var title_f37_5_37968="Intracardiac KCl";
var content_f37_5_37968=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Induced fetal demise: Intracardiac potassium chloride injection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The needle is seen within the fetal heart.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_5_37968=[""].join("\n");
var outline_f37_5_37968=null;
var title_f37_5_37969="Central venous cath PI";
var content_f37_5_37969=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F69685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F69685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Diagram showing central venous catheter for hemodialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 464px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows a central venous catheter, which is a thin, flexible tube. One end is put into a large vein, usually in the neck. The other end stays outside the body. During hemodialysis, the end outside of the body is connected to tubes from the dialysis machine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_5_37969=[""].join("\n");
var outline_f37_5_37969=null;
var title_f37_5_37970="Patient information: Hydronephrosis in adults (The Basics)";
var content_f37_5_37970=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17114\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/28/27072\">",
"         Anatomy of the urinary tract",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/32/37382\">",
"          Prostate gland",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?15/21/15698\">",
"         Patient information: Benign prostatic hyperplasia (enlarged prostate) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?42/56/43905\">",
"         Patient information: Kidney stones in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/3/2099\">",
"         Patient information: Prostate cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/51/28467\">",
"         Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/53/28499\">",
"         Patient information: Kidney stones in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/39/40565\">",
"         Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?41/41/42643\">",
"         Patient information: Treatment for advanced prostate cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hydronephrosis in adults (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hydronephrosis-in-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H26485881\">",
"      <span class=\"h1\">",
"       What is hydronephrosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hydronephrosis is another word for swelling of 1 or both kidneys. The kidneys are organs in the urinary tract that make urine (",
"      <a class=\"graphic graphic_figure graphicRef79864 \" href=\"mobipreview.htm?26/28/27072\">",
"       figure 1",
"      </a>",
"      ). Each kidney has 2 parts:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A part that filters the blood and removes waste and excess salt and water",
"       </li>",
"       <li>",
"        A part that collects the urine",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In hydronephrosis, the part of the kidney that collects the urine gets too much urine in it. This makes it swell and get bigger than normal.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26485896\">",
"      <span class=\"h1\">",
"       What causes hydronephrosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hydronephrosis happens when the urinary tract gets blocked. Then the urine can&rsquo;t drain, and it backs up into the kidney. Different conditions can cause a blockage in the urinary tract.",
"     </p>",
"     <p>",
"      In adults, the most common causes of a blockage are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Benign prostatic hyperplasia, or &ldquo;BPH&rdquo; &ndash; This is the medical term for an enlarged prostate. The prostate is an organ (in men) that surrounds the urethra (",
"        <a class=\"graphic graphic_figure graphicRef65675 \" href=\"mobipreview.htm?36/32/37382\">",
"         figure 2",
"        </a>",
"        ). The urethra is the tube the urine goes through before leaving the body. &nbsp;",
"       </li>",
"       <li>",
"        Cancer of the prostate or cancer of other organs in the lower belly &ndash; Cancer growths can push on the urinary tract to block the flow of urine.",
"       </li>",
"       <li>",
"        &ldquo;Stones&rdquo; in the urinary tract &ndash; Small &ldquo;stones&rdquo; can form from the salts and minerals that are normally in the urine. These stones can block the urinary tract.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Blockages can happen suddenly or slowly over time. They can affect 1 or both kidneys.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26485910\">",
"      <span class=\"h1\">",
"       What are the symptoms of hydronephrosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people with hydronephrosis have no symptoms, especially if the blockage happened slowly over time. They might find out they have hydronephrosis when their doctor does a test for another reason.",
"     </p>",
"     <p>",
"      When people do have symptoms, they usually include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Pain &ndash; People can have pain in their lower belly, genital area, sides, or lower back.",
"       </li>",
"       <li>",
"        Changes in urination &ndash; Hydronephrosis usually makes people urinate less than usual. But this doesn&rsquo;t always happen.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People can have other symptoms, too, depending on what&rsquo;s causing the blockage. For example, if the hydronephrosis is caused by BPH, symptoms might include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Needing to urinate often",
"       </li>",
"       <li>",
"        Having trouble starting to urinate",
"       </li>",
"       <li>",
"        Having a weak urine stream, or leaking or dribbling urine",
"       </li>",
"       <li>",
"        Feeling as though the bladder is not empty after urinating",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26485925\">",
"      <span class=\"h1\">",
"       Should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have the symptoms listed above, call your doctor or nurse. If you are not able to make any urine at all, call him or her right away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26485940\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will ask about your symptoms and do an exam. He or she will also do tests to check for the cause of your hydronephrosis and see how serious your condition is. These tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Urine tests",
"       </li>",
"       <li>",
"        Different types of imaging tests &ndash; Imaging tests create pictures of the inside of the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26485955\">",
"      <span class=\"h1\">",
"       How is hydronephrosis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You might not need any treatment if you have no symptoms, your blood test results are normal, and your kidneys are working normally.",
"     </p>",
"     <p>",
"      If you do need treatment, it will depend on your individual situation.",
"     </p>",
"     <p>",
"      To help urine drain out of your urinary tract, your doctor might put tubes in different parts of your urinary tract.",
"     </p>",
"     <p>",
"      If your blockage has caused an infection in your urinary tract, your doctor will prescribe antibiotics to treat the infection.",
"     </p>",
"     <p>",
"      Your doctor will also remove the blockage in your urinary tract. How your doctor does this will depend on what&rsquo;s causing the blockage. For example, BPH that causes hydronephrosis is usually treated with surgery to remove some of the prostate or shrink the prostate.",
"     </p>",
"     <p>",
"      If cancer is causing your hydronephrosis, your doctor will talk with you about your treatment options. Cancer can be treated in different ways, depending on the type of cancer.",
"     </p>",
"     <p>",
"      Stones in the urinary tract can be treated with:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A machine that uses sound waves to break up the stones",
"       </li>",
"       <li>",
"        Surgery to remove the stones",
"       </li>",
"       <li>",
"        A procedure called &ldquo;ureteroscopy&rdquo; in which a doctor puts a thin tube into the urethra. The tube has special tools on the end that the doctor can use to break up or remove the stones.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26486010\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/21/15698?source=see_link\">",
"       Patient information: Benign prostatic hyperplasia (enlarged prostate) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/3/2099?source=see_link\">",
"       Patient information: Prostate cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/56/43905?source=see_link\">",
"       Patient information: Kidney stones in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/51/28467?source=see_link\">",
"       Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/53/28499?source=see_link\">",
"       Patient information: Kidney stones in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/39/40565?source=see_link\">",
"       Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/41/42643?source=see_link\">",
"       Patient information: Treatment for advanced prostate cancer (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/5/37970?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17114 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-EBC78AF0D7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_5_37970=[""].join("\n");
var outline_f37_5_37970=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26485881\">",
"      What is hydronephrosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26485896\">",
"      What causes hydronephrosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26485910\">",
"      What are the symptoms of hydronephrosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26485925\">",
"      Should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26485940\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26485955\">",
"      How is hydronephrosis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26486010\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17114\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/28/27072\">",
"      Anatomy of the urinary tract",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/32/37382\">",
"       Prostate gland",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/51/28467?source=related_link\">",
"      Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/21/15698?source=related_link\">",
"      Patient information: Benign prostatic hyperplasia (enlarged prostate) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/53/28499?source=related_link\">",
"      Patient information: Kidney stones in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/56/43905?source=related_link\">",
"      Patient information: Kidney stones in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/3/2099?source=related_link\">",
"      Patient information: Prostate cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/39/40565?source=related_link\">",
"      Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/41/42643?source=related_link\">",
"      Patient information: Treatment for advanced prostate cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_5_37971="U-serrated pattern on direct immunofluorescence";
var content_f37_5_37971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    U-serrated IgG basement membrane zone antibody staining in epidermolysis bullosa acquisita by direct immunofluorescence microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 434px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The positive direct immunofluorescence staining along the basement membrane zone in this section of a perilesional skin specimen demonstrates what is described as a u-serrated linear pattern interspersed with segments of true linear IgG basement membrane zone antibody reactivity. This pattern is associated with epidermolysis bullosa acquisita and bullous systemic lupus erythematosus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_5_37971=[""].join("\n");
var outline_f37_5_37971=null;
var title_f37_5_37972="Carbinoxamine: Pediatric drug information";
var content_f37_5_37972=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Carbinoxamine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?11/8/11398?source=see_link\">",
"    see \"Carbinoxamine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/61/4053?source=see_link\">",
"    see \"Carbinoxamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F145677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Arbinoxa&trade;;",
"     </li>",
"     <li>",
"      Palgic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihistamine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/8/11398?source=see_link\">",
"      see \"Carbinoxamine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;2 years: 0.2-0.4 mg/kg/day divided 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Alternate dosing (manufacturer's recommendation);",
"     <b>",
"      Note:",
"     </b>",
"     When using this recommendation, be sure to compare with the weight-based dosage listed above as the age-based dosage may exceed 0.4 mg/kg/day in some individuals):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Palgic&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2-3 years: 2 mg (2.5 mL) 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     3-6 years: 2-4 mg (2.5-5 mL) 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;6 years: 4-6 mg (5-7.5 mL) 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 4-8 mg 3-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F145662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as maleate: 4 mg/5 mL (118 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Arbinoxa&trade;: 4 mg/5 mL (480 mL) [contains propylene glycol; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Palgic&reg;: 4 mg/5 mL (480 mL) [contains propylene glycol; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as maleate: 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Arbinoxa&trade;: 4 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Palgic&reg;: 4 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F145651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer without regard to food",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1057163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of symptoms of seasonal and perennial allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, urticaria, angioedema, and dermatographism",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13931076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F145693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Extrasystoles, hypotension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, confusion, coordination impaired (most frequent), dizziness (most frequent), euphoria, excitability, fatigue, headache, hysteria, insomnia, irritability, nervousness, neuritis, restlessness, sedation (most frequent), seizure, sleepiness (most frequent), vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Photosensitivity, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Early menses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, epigastric distress (most frequent), nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Difficult urination, urinary frequency, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, hemolytic anemia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Labyrinthitis, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchial secretions thickening (most frequent), chest tightness, nasal congestion, nasopharyngeal dryness, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, hypersensitivity reactions (including anaphylactic shock)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to carbinoxamine or any component of the formulation; use with or within 14 days of MAO inhibitor therapy; children &lt;2 years of age",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1057159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with mild to moderate hypertension, cardiovascular disease, diabetes, asthma, thyroid disease, increased intraocular pressure, GU or GI obstruction or symptomatic prostatic hypertrophy. May cause paradoxical excitation in young children.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1057158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety and efficacy for the use of cough and cold products in children &lt;2 years of age is limited. Serious adverse effects including death have been reported. The FDA notes that there are no approved OTC uses for these products in children &lt;2 years of age. Healthcare providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F145658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F145660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F145670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Maternal antihistamine use has generally not resulted in an increased risk of birth defects; however, information specific for the use of carbinoxamine during pregnancy has not been located. Although antihistamines are recommended for some indications in pregnant women, the use of other agents with specific pregnancy data may be preferred.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Carbinoxamine competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1057171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Duration: 3-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1057172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Half-life: Adults: 10-20 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1057165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/61/4053?source=see_link\">",
"      see \"Carbinoxamine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness or impair ability to perform activities requiring mental alertness or physical coordination; may cause blurred vision; may also cause CNS excitation and difficulty sleeping; may cause dry mouth; avoid alcohol; may rarely cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid direct exposure to sunlight",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12920 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-FDF33D9AD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_5_37972=[""].join("\n");
var outline_f37_5_37972=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145677\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057166\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057160\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145662\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145651\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057169\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057163\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057168\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13931076\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145693\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057173\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057159\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057158\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298972\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145658\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145660\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145670\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057157\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057171\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057172\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057165\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12920\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12920|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/8/11398?source=related_link\">",
"      Carbinoxamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/61/4053?source=related_link\">",
"      Carbinoxamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_5_37973="Amsacrine: Drug information";
var content_f37_5_37973=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amsacrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/30/10725?source=see_link\">",
"    see \"Amsacrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2935690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      AMSA PD",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F553980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F135281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute leukemia:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Induction: 75-125 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 3-4 weeks (125 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day is preferred; two courses may be necessary to achieve induction; increase dose by 20% in second and subsequent cycles if marrow hypoplasia not achieved and in absence of significant toxicity in previous course.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance: Once remission has been achieved, maintenance dose should be ~50% of induction dose, administered every 4-8 weeks, depending on blood counts and marrow recovery",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2984721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F135282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;\">",
"     Dosage reduction recommended; specific guidelines from the manufacturer are not available; the following guidelines have been used by some clinicians:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hall, 1983:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Serum creatinine 1.2-1.8 mg/dL: No adjustment recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Serum creatinine 2-3 mg/dL, oliguric patients: Administer 60% to 70% of dose; may increase subsequent dose based on toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hornedo, 1985: BUN &gt;20 mg/dL or serum creatinine &gt;1.5 mg/dL: Administer 75% of dose",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F135283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Bilirubin &gt;2 mg/dL: Dosage reduction recommended; specific guidelines from the manufacturer are not available; the following guidelines have been used by some clinicians:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hall, 1983: Bilirubin &gt;2 mg/dL: Administer 60% to 70% of dose; may increase subsequent dose based on toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hornedo, 1985: Bilirubin &gt;2 mg/dL: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Koren, 1992: Severe hepatic dysfunction: Administer &le;50% of dose",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F6160824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Consider decreasing dose by 20% if life-threatening infection or hemorrhage occurred in previous cycle; delay second and subsequent cycles until recovery from myelosuppression or evidence of leukemic infiltrate is evident.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5944475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     AMSA PD: 50 mg/mL (1.5 mL) [supplied with L-lactic acid 0.0353 M 13.5 mL]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11216951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F135266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Infuse over 60-90 minutes; avoid extravasation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F135316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W;",
"     <b>",
"      incompatible",
"     </b>",
"     with D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      10",
"     </sub>",
"     NS, NS, LR, chloride ion. Amsacrine forms an immediate precipitate in the presence of chloride ion; do not mix with drugs that are chloride or hydrochloride salts.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amikacin, chlorpromazine, clindamycin, cytarabine, dexamethasone, diphenhydramine, famotidine, fludarabine, gentamicin, haloperidol, hydrocortisone sodium succinate, hydromorphone, lorazepam, morphine, prochlorperazine, promethazine, ranitidine, tobramycin, vancomycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, amphotericin B, aztreonam, calcium chloride, ceftazidime, ceftriaxone, cimetidine, furosemide, ganciclovir, heparin, methylprednisolone, metoclopramide, ondansetron, potassium chloride, sargramostim.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Granisetron.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6160689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refractory acute leukemia",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F135307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute myeloid leukemia (AML)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F135309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (&gt;10%), vomiting (&gt;10%), stomatitis (&gt;10%), diarrhea (&gt;10%), perirectal abscess (&gt;10%), abdominal pain (&gt;10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Myelosuppression, leukopenia (nadir: 11-13 days; recovery: days 17-25)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Atrial tachyarrhythmia, atrial tachycardia, atrial fibrillation, bradycardia, cardiomyopathy (rare), cardiopulmonary arrest, CHF (rare); ECG changes (QT prolongation, nonspecific ST segment or T wave changes); ejection fraction decreased, hypotension, sinus tachycardia, tachycardia, ventricular arrhythmia, ventricular extrasystoles, ventricular fibrillation, ventricular tachyarrhythmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, dizziness, emotional lability, fever, headache, hypoesthesia, lethargy, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, cutaneous inflammatory reaction, dermatologic reaction, purpura, rash (purpuric or maculopapular), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, dysphagia, gingivitis, gum hemorrhage, hematemesis, weight changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Orange-red discoloration of the urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, granulocytopenia, hemorrhage, pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, AST increased, bilirubin increased, hepatic insufficiency, hepatitis, hepatotoxicity, jaundice, progressive liver failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site inflammation, phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Musculoskeletal pain, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, creatinine increased, hematuria, proteinuria, renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F135269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amsacrine, acridine derivatives, or any component of the formulation; pre-existing bone marrow suppression due to chemotherapy or radiation therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F135260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Myelosuppression, including transient leukopenia, is a common toxicity; prolonged marrow aplasia may occur. May require dose reduction, therapy interruption or treatment delay.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: Acute cardiotoxicity, including arrhythmia, ECG changes, and rarely, cardiomyopathy and CHF, have been reported with use, although generally not considered to be a cumulative dose effect. Risk factors for cardiotoxicity may include hypokalemia and a history of anthracycline therapy. Correct fluid and electrolyte imbalance prior to treatment initiation. Use with caution in patients with underlying cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor lysis syndrome: Tumor lysis syndrome may occur; adequate hydration and prophylactic uric acid reduction should be considered prior to or during treatment; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with significant hepatic impairment (bilirubin &gt;2 mg/dL); toxicity may be increased. Hepatic metabolism and biliary excretion are major routes of elimination. Dosage reductions may be recommended. Evaluate hepatic function prior to and during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Serum potassium should be &gt;4 mEq/L prior to administration (Arlin, 1988). The risk for arrhythmia is decreased by ensuring normal potassium levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with significant renal impairment (BUN &gt;20 mg/dL; serum creatinine &gt;1.2 mg/dL); toxicity may be increased. Dosage reductions may be recommended. Evaluate renal function prior to and during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anthracyclines: Use with caution in patients who have received high cumulative doses of anthracyclines (may increase the risk for cardiotoxicity).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccinations: Avoid vaccination with live virus vaccines during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6217944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6160690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Women of childbearing potential should avoid becoming pregnant while receiving treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6160692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6160693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Breast-feeding should be discontinued prior to treatment.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6160887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, bone marrow studies, serum potassium, hepatic function, renal function; ECG (during and after infusion)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F135271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Amekrin (DK, SE);",
"     </li>",
"     <li>",
"      Amsalyo (FR);",
"     </li>",
"     <li>",
"      Amsidine (BE, GB, IE, NL);",
"     </li>",
"     <li>",
"      Amsidyl (AU, CH, KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F135259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Amsacrine has been shown to inhibit DNA synthesis by binding to, and intercalating with, DNA; inhibits topoisomerase II activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F135268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.67 L/kg; minimal CNS penetration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 96% to 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, to inactive metabolites (major metabolite is 5&prime; glutathione conjugate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1.4-5 hours; Terminal: 8-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Bile; urine (35%; 20% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Arlin ZA, &ldquo;A Special Role for Amsacrine in the Treatment of Acute Leukemia,&rdquo;",
"      <i>",
"       Cancer Invest",
"      </i>",
"      , 1989, 7(6):607-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/5/37973/abstract-text/2630010/pubmed\" id=\"2630010\" target=\"_blank\">",
"        2630010",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arlin ZA, Feldman, E. Kempin S, et al, &ldquo;Amsacrine With High-Dose Cytarabine is Highly Effective Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia in Adults,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1988, 72(2):433-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/5/37973/abstract-text/3165293/pubmed\" id=\"3165293\" target=\"_blank\">",
"        3165293",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hall SW, Friedman J, Legha SS, et al, &ldquo;Human Pharmacokinetics of a New Acridine Derivative, 4'-(9-Acridinylamino)methanesulfon-m-anisidide (NSC 249992),&rdquo;",
"      <i>",
"       Cancer Res",
"      </i>",
"      , 1983, 43(7):3422-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/5/37973/abstract-text/6687834/pubmed\" id=\"6687834\" target=\"_blank\">",
"        6687834",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hornedo J and Van Echo DA, &ldquo;Amsacrine (m-AMSA): A New Antineoplastic Agent. Pharmacology, Clinical Activity and Toxicity,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1985, 5(2):78-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/5/37973/abstract-text/2582401/pubmed\" id=\"2582401\" target=\"_blank\">",
"        2582401",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koren G, Beatty K, Seto A, et al, &ldquo;The Effects of Impaired Liver Function on the Elimination of Antineoplastic Agents,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1992, 26(3):363-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/5/37973/abstract-text/1554959/pubmed\" id=\"1554959\" target=\"_blank\">",
"        1554959",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Louie AC and Issell BF, &ldquo;Amsacrine (AMSA) - A Clinical Review,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1985, 3(4):562-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/5/37973/abstract-text/3884748/pubmed\" id=\"3884748\" target=\"_blank\">",
"        3884748",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pai VB and Nahata MC, &ldquo;Cardiotoxicity of Chemotherapuetic: Incidence, Treatment and Prevention,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 2000, 22(4):263-302.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/5/37973/abstract-text/10789823/pubmed\" id=\"10789823\" target=\"_blank\">",
"        10789823",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9343 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-95F309B6B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_5_37973=[""].join("\n");
var outline_f37_5_37973=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2935690\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F553980\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135281\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984721\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135282\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135283\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6160824\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5944475\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11216951\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135266\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135316\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6160689\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135307\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135309\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135269\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135260\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298750\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6217944\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6160690\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6160692\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6160693\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6160887\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135271\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135259\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135268\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9343\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9343|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/30/10725?source=related_link\">",
"      Amsacrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_5_37974="Pegylated interferon (peginterferon) alfa-2b and ribavirin: Patient drug information";
var content_f37_5_37974=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pegylated interferon (peginterferon) alfa-2b and ribavirin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/8/37000?source=see_link\">",
"     see \"Pegylated interferon (peginterferon) alfa-2b and ribavirin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F207103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pegetron&reg;;",
"     </li>",
"     <li>",
"      Pegetron&reg; RediPen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692163",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This product is made up of 2 drugs, ribavirin and peginterferon alfa-2b. They are used at the same time to treat some patients with hepatitis C infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702691",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to peginterferon alfa-2b, ribavirin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3744704",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Autoimmune disease, very bad kidney disease, very bad liver disease, very bad mental disease, seizures, or thyroid disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701069",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are of childbearing age, but are not using 2 kinds of birth control or if you are planning to get pregnant during your care or within 6 months after care has ended.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with a sex partner who is pregnant or plans on getting pregnant at any time while you are being treated or within 6 months after your care has ended.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703869",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have used interferon before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697182",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been treated for hepatitis C infection before with this drug and it did not work, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697192",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have cancer, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2956564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gout, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697263",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have hepatitis B or HIV disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697341",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have sickle cell disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks. Alcohol may make liver disease worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697774",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use 2 kinds of birth control that you can trust while using this drug and for 6 months after stopping this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy during care and for 6 months after care ends. Use 2 kinds of birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. Mild pain drugs may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair thinning.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark, tarry-black stool.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698669",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug or within 6 months after care ends.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698676",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For men, if your woman partner gets pregnant while you are being treated or within 6 months after care ends.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698519",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a woman of childbearing age, take a monthly pregnancy test.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705521",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Ribavirin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Peginterferon alfa-2b:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime to help with flu-like signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw syringe away after use. Do not use more than one time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705521",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Ribavirin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Peginterferon alfa-2b:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696511",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you miss 3 days of this drug, call your doctor to find out what to do.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose, brand, or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699534",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store ribavirin in a refrigerator or at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699525",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store peginterferon in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12041 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-B6FAD70B64-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_5_37974=[""].join("\n");
var outline_f37_5_37974=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207103\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028098\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028100\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028099\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028104\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028105\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028107\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028102\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028103\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028108\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028109\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?36/8/37000?source=related_link\">",
"      Pegylated interferon (peginterferon) alfa-2b and ribavirin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_5_37975="H pylori and GERD";
var content_f37_5_37975=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    H. pylori and GERD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 591px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The effect of Helicobacter pylori (H. pylori) on gastroesophageal reflux disease (GERD) is dependent on the distribution of the gastritis and the predisposition for GERD (esophagogastric junction (EGJ) competence, hiatus hernia, esophageal acid clearance).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_5_37975=[""].join("\n");
var outline_f37_5_37975=null;
var title_f37_5_37976="Management of couples with recurrent pregnancy loss";
var content_f37_5_37976=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of couples with recurrent pregnancy loss",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/5/37976/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/5/37976/contributors\">",
"     Togas Tulandi, MD, MHCM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/5/37976/contributors\">",
"     Haya M Al-Fozan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/5/37976/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/5/37976/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/5/37976/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/5/37976/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/5/37976/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;High quality data on management of recurrent pregnancy loss (RPL) are limited; therefore, therapeutic recommendations are largely based upon clinical experience and data from observational studies. Nevertheless, the prognosis for a successful future pregnancy is generally good: the overall live birth rates after normal and abnormal diagnostic evaluations for RPL are 77 and 71 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapeutic intervention is guided by the underlying cause of RPL. In all cases, emotional support is important in caring for these often anxious couples, and may enhance therapeutic success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of RPL will be discussed here. Causes and evaluation of RPL are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/6/8298?source=see_link\">",
"     \"Definition and etiology of recurrent pregnancy loss\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26679?source=see_link\">",
"     \"Evaluation of couples with recurrent pregnancy loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PARENTAL KARYOTYPE ABNORMALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Couples in whom chromosomal abnormalities are discovered in one or both partners or the abortus are generally referred for genetic counseling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/5\">",
"     5",
"    </a>",
"    ]. They should receive information regarding the probability of having a chromosomally normal or abnormal conception in the future. In the latter case, the risk of miscarriage and bearing a chromosomally abnormal offspring who may be phenotypically normal or abnormal and a carrier of a chromosomal defect should be discussed. The magnitude of these risks varies according to the specific chromosomal abnormality and the sex of the carrier parent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18167?source=see_link\">",
"     \"Chromosomal translocations, deletions, and inversions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/0/23562?source=see_link\">",
"     \"Congenital cytogenetic abnormalities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Couples with karyotypic abnormalities may choose to undergo prenatal genetic studies, such as amniocentesis or chorionic villus sampling, to determine the fetal karyotype. Pregnancy termination is an option if the fetus is affected. In vitro fertilization (IVF) with preimplantation genetic diagnosis (PGD) can be used to avoid transfer and implantation of an affected embryo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. PGD improves the pregnancy outcome of translocation carriers with a history of repeated pregnancy loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/9\">",
"     9",
"    </a>",
"    ]. On the other hand, this procedure reduces the live birth rate after IVF if preimplantation testing is performed solely because of advanced maternal age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23431?source=see_link\">",
"     \"Preimplantation genetic diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gamete donation (egg or sperm), surrogacy, and adoption are methods of preventing conception of an affected embryo. The choice depends upon the specific abnormality and parental preference. (See individual topic reviews on these topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     UTERINE ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine abnormalities are managed surgically if the defect is a surgically correctable cause of pregnancy loss, such as a uterine septum, intrauterine adhesions, or submucosal myoma. These conditions can be treated hysteroscopically. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/21/29014?source=see_link\">",
"     \"Surgical management of congenital uterine anomalies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26101?source=see_link\">",
"     \"Intrauterine adhesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30662?source=see_link\">",
"     \"Reproductive issues in women with uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no randomized trials evaluating pregnancy outcome after surgical correction of uterine anomalies. In a classic observational series, repair of bicornuate and septate uteri reduced the abortion rate from 84 percent (before surgery) to 12 percent (after surgery) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/11\">",
"     11",
"    </a>",
"    ]. The problem with this and similar studies is use of patients as their own controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/12-17\">",
"     12-17",
"    </a>",
"    ]. However, studies using better control groups also support the efficacy of surgical correction of uterine defects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study, the probability of conception and live birth in women after hysteroscopic metroplasty was significantly higher than in women with unexplained infertility (live birth rate 34.1 versus 18.9 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, the effect of uterine septum on IVF outcome was investigated in 289 embryo transfers before and 538 embryo transfers after hysteroscopic resection of uterine septum and in a control group that underwent two consecutive embryo transfers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/19\">",
"       19",
"      </a>",
"      ]. For women with a large septum, the live birth rate was 2.7 percent before surgery and 15.6 percent after surgery versus 20.9 percent in the control group. For women with a small septum, the live birth rate was 2.8 percent before surgery and 18.6 percent after surgery versus 21.9 percent in the control group. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The value of prophylactic cervical cerclage in women with a uterine anomaly, but no history of second trimester pregnancy loss, is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/20\">",
"     20",
"    </a>",
"    ]. We do not advocate prophylactic cervical cerclage in women with no history of cervical insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4457?source=see_link\">",
"     \"Cervical insufficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/42/37544?source=see_link\">",
"     \"Transvaginal cervical cerclage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32532?source=see_link\">",
"     \"Transabdominal cervical cerclage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A gestational carrier is an option for women with irreparable uterine defects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15015?source=see_link\">",
"     \"Surrogate pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANTIPHOSPHOLIPID SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    appear to improve pregnancy outcome in women with antiphospholipid syndrome who have recurrent fetal losses. There is controversy about the benefit of such therapy in selected women with recurrent embryonic losses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/0/44041?source=see_link\">",
"     \"Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SUSPECTED IMMUNOLOGIC DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no alloimmune mechanism has been proven to cause RPL, several immunologic treatments have been advocated to improve the live birth rate in women with previous unexplained RPL. None are effective, and some appear to be harmful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/21-27\">",
"     21-27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systematic reviews have consistently found no beneficial effect of immunotherapy for treatment of RPL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/22,24,28,29\">",
"     22,24,28,29",
"    </a>",
"    ]. The general findings are illustrated by the following two examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review of 20 trials of high quality showed that immunotherapy did not result in a statistically significant improvement in live births compared to untreated controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/22\">",
"       22",
"      </a>",
"      ]. Four types of immunotherapy were evaluated: paternal cell immunization (OR 1.23, 95% CI 0.89-1.70; 12 studies including 641 participants); third party donor cell immunization (OR 1.39, 95% CI 0.68-2.82; three studies including 156 participants); trophoblast membrane infusion (OR 0.40, 95% CI 0.11-1.45; one study including 37 participants); and intravenous immune globulin (OR 0.98, 95% CI 0.61-1.58; eight studies including 303 participants).",
"     </li>",
"     <li>",
"      Another systematic review evaluated three randomized and two cohort trials of immunotherapy treatment specifically in patients who failed IVF; a total of 373 patients were involved in these trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/28\">",
"       28",
"      </a>",
"      ]. Patients treated with IVIG showed a consistently higher live birth rate than untreated controls; this benefit was statistically significant when the trial results were pooled in meta-analysis. However, there were many differences among these trials, such as the preparations used, the timing of the intervention (preconception, postconception, both), and dosage, as well as the immunological abnormalities of the patients. In addition, some controls received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      while others did not receive any therapy. Thus, appropriate use of this therapy remains unclear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immune therapy of RPL should be considered experimental, and used only in the setting of a clinical trial regulated by an Institutional Review Board.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids have several anti-inflammatory effects, including suppression of natural killer cell activity, but do not appear to be effective for preventing RPL. This was illustrated by a trial in which 202 women with RPL and a variety of autoantibodies (antinuclear, anti-DNA, antilymphocyte, anticardiolipin, lupus anticoagulant) were randomly assigned to receive either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (0.5 to 0.8 mg per kilogram of body weight per day) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (100 mg per day) or placebo for the duration of the pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/26\">",
"     26",
"    </a>",
"    ]. The two groups did not have a statistically significant difference in rate of live birth (66 and 56 percent, respectively).",
"   </p>",
"   <p>",
"    Oral administration of glucocorticoids for treatment of RPL has been abandoned because of uncertain efficacy and a clearly demonstrable increase in complications, such as preterm premature rupture of membranes, gestational diabetes, and maternal hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Alternative methods of glucocorticoid treatment, which are under investigation, may be safer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     THYROID DYSFUNCTION AND DIABETES MELLITUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with overt thyroid disease or diabetes mellitus should be treated, as medically appropriate, since these disorders can result in serious sequelae. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link\">",
"     \"Overview of medical care in adults with diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21143?source=see_link\">",
"     \"Treatment of Graves' hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3850?source=see_link\">",
"     \"Subclinical hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with elevated serum thyroid peroxidase antibody concentrations are at high risk of developing hypothyroidism in the first trimester and autoimmune thyroiditis postpartum, and should be followed appropriately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/30\">",
"     30",
"    </a>",
"    ]. Euthyroid women with high serum thyroid peroxidase antibody concentrations may benefit from treatment with thyroid hormone during pregnancy as this therapy may reduce the risk of miscarriage and preterm birth. In a randomized trial, administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    (median dose 50 mcg daily) to early pregnant euthyroid women with positive thyroid peroxidase antibodies decreased the miscarriage rate from 13.8 to 3.5 percent (RR 1.72, 95% CI 1.13-2.25) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, the incidence of premature deliveries in treated women was lower than in those who were not treated (7 versus 22.4 percent, RR 1.66, 95% CI 1.18-2.34). A limitation of this study is that the mean gestational age of starting therapy was 10 weeks, and all but one of the losses had occurred at less than 11 weeks. Further study is required to evaluate the efficacy of levothyroxine in women with RPL and positive thyroid peroxidase antibodies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16186?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of thyroid disease in pregnancy\", section on 'Thyroid peroxidase antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     POLYCYSTIC OVARY SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The miscarriage rate in women with polycystic ovary syndrome (PCOS) is 20 to 40 percent, higher than the baseline rate in the general obstetric population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/32\">",
"     32",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    has been used in women with PCOS to decrease this risk, but the effectiveness of this approach is unproven. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16826?source=see_link&amp;anchor=H21#H21\">",
"     \"Metformin for treatment of the polycystic ovary syndrome\", section on 'Spontaneous abortion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HYPERPROLACTINEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal circulating levels of prolactin may play an important role in maintaining early pregnancy. A study of 64 hyperprolactinemic women with RPL randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    therapy or no bromocriptine found treatment was associated with a significantly higher rate of successful pregnancy (86 versus 52 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/33\">",
"     33",
"    </a>",
"    ]. Prolactin levels during early pregnancy were significantly greater in women who miscarried. We suggest treatment of women with hyperprolactinemia and RPL, even in the absence of overt hypogonadism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31561?source=see_link\">",
"     \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     THROMBOPHILIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation of women with certain inherited thrombophilias may improve maternal outcome (eg, prevention of venous thromboembolism), but does not appear to prevent pregnancy loss. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     UNEXPLAINED RPL",
"    </span>",
"    &nbsp;&mdash;&nbsp;After evaluation, RPL remains unexplained in approximately one-half of couples. Nevertheless, the chance of a live birth is good, ie, over 50 percent with no intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/34\">",
"     34",
"    </a>",
"    ]. This rate must be considered in evaluating therapies for unexplained RPL.",
"   </p>",
"   <p>",
"    Treatments that have been offered to couples with unexplained RPL, ranked in order of low to high risk, simplicity, and expense to the patient, include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Lifestyle modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiological studies suggest that lifestyle modifications can increase fertility potential, although these have not been definitively tested in randomized trials. These modifications include eliminating use of tobacco products, alcohol, and caffeine and reduction in body mass index (for obese women). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11482?source=see_link\">",
"     \"Optimizing natural fertility in couples planning pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Progesterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large randomized trials demonstrating the efficacy of progesterone treatment in RPL are lacking, but the drug is commonly prescribed for this indication. Meta-analyses of available randomized and semi-randomized trials of progesterone versus placebo or no treatment in women with unexplained RPL have shown a significant benefit (risk of RPL with progesterone OR 0.4 to 0.5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. However, the use of progesterone to prevent RPL remains controversial because of the small total number of women treated with progesterone in these trials (&lt;140), wide confidence intervals in most trials, and significant methodological problems in study design. Large, well-designed randomized trials are needed.",
"   </p>",
"   <p>",
"    We typically prescribe progesterone (200 mg three times daily, vaginally) as empiric treatment of unexplained RPL. It is started three days after the LH surge, so as not to inhibit ovulation, and continued until 10 weeks of gestation, when placental progesterone production should be fully functional. Alternatively, progesterone in gel (90 mg vaginally once daily) or micronized progesterone (100 mg orally, two to three tablets per day) can be administered. The therapeutic effect of progesterone may be related to immune modulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Aspirin with or without heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large randomized trial found that neither",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    alone nor aspirin plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    improved the live-birth rate of women with unexplained RPL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/38\">",
"     38",
"    </a>",
"    ]. In this trial, 364 women with unexplained RPL after a thorough evaluation were randomly assigned to receive daily aspirin (80 mg), aspirin plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/41/27286?source=see_link\">",
"     nadroparin",
"    </a>",
"    (2850 international units), or placebo. Aspirin or placebo was begun preconceptionally and nadroparin was started as soon as a viable pregnancy was documented by ultrasound. Among the 299 women who became pregnant, the live-birth rates for combination therapy, aspirin alone, and placebo were not significantly different: 69, 62, and 67 percent, respectively.",
"   </p>",
"   <p>",
"    Similarly, another trial randomly assigned 294 women with &ge;2 consecutive unexplained pregnancy losses at &le;24 weeks to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    and low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or no treatment; both groups received intensive pregnancy surveillance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/39\">",
"     39",
"    </a>",
"    ]. Medical therapy did not reduce the rate of pregnancy loss, which was 22 percent with drug treatment and 20 percent without it.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Human chorionic gonadotropin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/60/26564?source=see_link\">",
"     Human chorionic gonadotropin",
"    </a>",
"    (hCG) therapy during early gestation may be useful in preventing miscarriage since endogenous hCG is known to play a critical role in the establishment of pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/26\">",
"     26",
"    </a>",
"    ]. A systematic review of four trials involving 180 women with RPL found hCG therapy was associated with a significantly reduced risk of miscarriage (OR 0.26, 95% CI 0.14-0.52), particularly in women with oligomenorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/40\">",
"     40",
"    </a>",
"    ]. However, there were important methodological weaknesses in two of these studies. To date, there is insufficient evidence to recommend the use of hCG to prevent pregnancy loss in women with a history of unexplained RPL. Large randomized controlled trials are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Human menopausal gonadotropin",
"    </span>",
"    &nbsp;&mdash;&nbsp;An observational study reported that controlled ovarian stimulation via human menopausal gonadotropin (hMG) administration appeared effective for treatment of endometrial defects in women with RPL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/41\">",
"     41",
"    </a>",
"    ]. The mechanism may be correction of a luteal phase defect or stimulation of a thicker endometrium, thus leading to a better implantation site. Our clinical experience supports the efficacy of this treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Clomiphene citrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;By increasing serum FSH,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate increases follicular number and serum estradiol levels, which should lead to an increase in the number of corpora lutea and a higher midluteal progesterone concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/42\">",
"     42",
"    </a>",
"    ]. Two randomized trials comparing clomiphene to progesterone for treatment of inadequate luteal phase demonstrated similar pregnancy rates (20 to 30 percent) with each treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Clomiphene, unlike progesterone, does not prolong the luteal phase, thereby lessening the anxiety and period of uncertainty of infertile couples concerning possible conception. Due to the anti-estrogen effect of clomiphene on the endometrium, we do not use clomiphene in women with RPL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     In vitro fertilization and preimplantation genetic diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies evaluating the value of in vitro fertilization (IVF) in women with RPL have yielded mixed results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. Embryos of women with unexplained RPL have a higher incidence of aneuploidy for chromosomes 13,16,18, 21, 22, X, and Y than embryos obtained from healthy women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/49\">",
"     49",
"    </a>",
"    ]. However, the value of preimplantation genetic screening in this setting has not been proven. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23431?source=see_link\">",
"     \"Preimplantation genetic diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Gestational carrier",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with RPL or recurrent IVF implantation failures not associated with recurrent embryonic aneuploidy or obvious intrinsic gamete factors (eg, single gene defects, diminished oocyte and embryo quality) may consider use of a gestational carrier. Women who decide to pursue this route should undergo a thorough evaluation as to the etiology of the RPL or failed IVF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15015?source=see_link\">",
"     \"Surrogate pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Oocyte donation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor quality oocytes may be responsible for 25 percent of pregnancy losses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/50\">",
"     50",
"    </a>",
"    ]. Ovum donation can overcome this problem and has been associated with a live birth rate of 88 percent in women with RPL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/50\">",
"     50",
"    </a>",
"    ]. The success of ovum donation, even when the male partner's sperm is utilized for fertilization, suggests the absence of a significant paternal contribution to the etiology of RPL. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24807?source=see_link\">",
"     \"Oocyte donation for assisted reproduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An observational study compared 50 pregnant women who were treated before and during pregnancy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    progesterone (20",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and folate (5 mg every second day) with 52 women who were not treated during the same observation period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/51\">",
"     51",
"    </a>",
"    ]. The first trimester miscarriage rate was 19 percent in the treated group and 63 percent in the control group; this difference was not statistically significant. The live birth rate in the treated group and control groups was 77 and 35 percent, respectively (P = 0.04). With combined treatment of four agents, it is unclear which of the treatments was beneficial. The nonrandomized design and small number of cases also limits the usefulness of this study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     FUTURE PREGNANCY PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26414623\">",
"    <span class=\"h2\">",
"     Continued pregnancy loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;The greatest risk of recurrent loss occurs during the period up to the time of previous miscarriage.",
"   </p>",
"   <p>",
"    The likelihood of successful pregnancy in women with a history of recurrent pregnancy loss (RPL) was evaluated in a single center cohort study of 987 women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/52\">",
"     52",
"    </a>",
"    ]. At five years after the initial visit to a tertiary care center for RPL, 67 percent of women had a live birth. Increasing maternal age and a higher number of miscarriages at time of initial visit were associated with a significant decrease in the likelihood of having a live birth. Another study of women with unexplained recurrent pregnancy loss showed that 167 of 222 women who conceived subsequently had a successful pregnancy beyond 24 weeks of gestation (75 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In women with recurrent early first trimester pregnancy loss, the presence of fetal cardiac activity is reassuring of subsequent viable delivery, although the pregnancy loss rate remains above that of the general population. A literature review of studies examining fetal loss rates after sonographic demonstration of fetal cardiac activity reported the rate of such losses in women with RPL was 5 to 22 percent compared to 7 to 15 percent in infertile populations and 3 to 6 percent in controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Second trimester pregnancy loss is significantly associated with recurrent second trimester loss and future spontaneous preterm birth. After a second trimester pregnancy loss, one study reported 39 percent of women had a preterm delivery in their next pregnancy, 5 percent had a stillbirth, and 6 percent had a neonatal death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/55\">",
"     55",
"    </a>",
"    ]. In another study of 30 women with second trimester loss, the frequency of recurrent second trimester loss was 27 percent and the frequency of subsequent preterm birth was 33 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26414616\">",
"    <span class=\"h2\">",
"     Other obstetric issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a history of RPL who become pregnant may be at higher risk for developing fetal growth restriction and premature delivery, but not for gestational hypertension or diabetes. As an example, one study of 162 women with RPL who progressed beyond 24 weeks of gestation reported the rates of preterm delivery (13 percent), fetal growth restriction (13 percent), perinatal loss (2.5 percent) and cesarean delivery (36 percent) were significantly higher than those of the control group (approximately 4, 2, 1, and 17 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37976/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Obstetric management depends upon the underlying cause of RPL, if known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    Basics topics (see",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/62/20450?source=see_link\">",
"     \"Patient information: Repeated miscarriage (The Basics)\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Couples in whom chromosomal abnormalities are discovered in one or both partners or the abortus are generally referred for genetic counseling, which should include information about the probability of having a chromosomally normal or abnormal conception, and options for managing this risk. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Parental karyotype abnormality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Uterine abnormalities are managed surgically if the defect is a surgically correctable cause of pregnancy loss, such as a uterine septum, intrauterine adhesions, or submucosal myoma. These conditions can be treated hysteroscopically. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Uterine abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <strong>",
"       not",
"      </strong>",
"      using immunotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ) or glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ) for treatment of RPL. These drugs are not effective and may be harmful. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Immunotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment of women with hyperprolactinemia and RPL (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Hyperprolactinemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of treatments have been offered to couples with unexplained RPL. We start with low risk, simple, and less expensive interventions and, if unsuccessful, move on to higher risk, more complex and expensive options. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Unexplained RPL'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with a history of RPL who become pregnant may be at higher risk for developing fetal growth restriction and premature delivery. Detection of fetal cardiac activity in early pregnancy is reassuring of subsequent viable delivery, although the pregnancy loss rate remains above that of the general population. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Future pregnancy prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/1\">",
"      Harger JH, Archer DF, Marchese SG, et al. Etiology of recurrent pregnancy losses and outcome of subsequent pregnancies. Obstet Gynecol 1983; 62:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/2\">",
"      Stray-Pedersen B, Stray-Pedersen S. Etiologic factors and subsequent reproductive performance in 195 couples with a prior history of habitual abortion. Am J Obstet Gynecol 1984; 148:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/3\">",
"      Liddell HS, Pattison NS, Zanderigo A. Recurrent miscarriage--outcome after supportive care in early pregnancy. Aust N Z J Obstet Gynaecol 1991; 31:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/4\">",
"      Clifford K, Rai R, Regan L. Future pregnancy outcome in unexplained recurrent first trimester miscarriage. Hum Reprod 1997; 12:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/5\">",
"      Laurino MY, Bennett RL, Saraiya DS, et al. Genetic evaluation and counseling of couples with recurrent miscarriage: recommendations of the National Society of Genetic Counselors. J Genet Couns 2005; 14:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/6\">",
"      Egozcue J, Santal&oacute; J, Gim&eacute;nez C, et al. Preimplantation genetic diagnosis. Mol Cell Endocrinol 2000; 166:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/7\">",
"      Munn&eacute; S, Cohen J, Sable D. Preimplantation genetic diagnosis for advanced maternal age and other indications. Fertil Steril 2002; 78:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/8\">",
"      Werlin L, Rodi I, DeCherney A, et al. Preimplantation genetic diagnosis as both a therapeutic and diagnostic tool in assisted reproductive technology. Fertil Steril 2003; 80:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/9\">",
"      Otani T, Roche M, Mizuike M, et al. Preimplantation genetic diagnosis significantly improves the pregnancy outcome of translocation carriers with a history of recurrent miscarriage and unsuccessful pregnancies. Reprod Biomed Online 2006; 13:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/10\">",
"      Mastenbroek S, Twisk M, van Echten-Arends J, et al. In vitro fertilization with preimplantation genetic screening. N Engl J Med 2007; 357:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/11\">",
"      Heinonen PK, Saarikoski S, Pystynen P. Reproductive performance of women with uterine anomalies. An evaluation of 182 cases. Acta Obstet Gynecol Scand 1982; 61:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/12\">",
"      March CM, Israel R. Gestational outcome following hysteroscopic lysis of adhesions. Fertil Steril 1981; 36:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/13\">",
"      Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/14\">",
"      March CM, Israel R. Hysteroscopic management of recurrent abortion caused by septate uterus. Am J Obstet Gynecol 1987; 156:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/15\">",
"      Valle RF, Sciarra JJ. Hysteroscopic treatment of the septate uterus. Obstet Gynecol 1986; 67:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/16\">",
"      Fayez JA. Comparison between abdominal and hysteroscopic metroplasty. Obstet Gynecol 1986; 68:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/17\">",
"      Patton PE, Novy MJ, Lee DM, Hickok LR. The diagnosis and reproductive outcome after surgical treatment of the complete septate uterus, duplicated cervix and vaginal septum. Am J Obstet Gynecol 2004; 190:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/18\">",
"      Mollo A, De Franciscis P, Colacurci N, et al. Hysteroscopic resection of the septum improves the pregnancy rate of women with unexplained infertility: a prospective controlled trial. Fertil Steril 2009; 91:2628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/19\">",
"      Toma��evi�� T, Ban-Frange�� H, Virant-Klun I, et al. Septate, subseptate and arcuate uterus decrease pregnancy and live birth rates in IVF/ICSI. Reprod Biomed Online 2010; 21:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/20\">",
"      Ansari AH, Kirkpatrick B. Recurrent pregnancy loss. An update. J Reprod Med 1998; 43:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/21\">",
"      Cowchock FS, Reece EA, Balaban D, et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992; 166:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/22\">",
"      Porter TF, LaCoursiere Y, Scott JR. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev 2006; :CD000112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/23\">",
"      Ober C, Karrison T, Odem RR, et al. Mononuclear-cell immunisation in prevention of recurrent miscarriages: a randomised trial. Lancet 1999; 354:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/24\">",
"      Hutton B, Sharma R, Fergusson D, et al. Use of intravenous immunoglobulin for treatment of recurrent miscarriage: a systematic review. BJOG 2007; 114:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/25\">",
"      Laskin CA, Bombardier C, Hannah ME, et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997; 337:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/26\">",
"      Regan L, Rai R. Epidemiology and the medical causes of miscarriage. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/27\">",
"      Ogasawara M, Aoki K. Successful uterine steroid therapy in a case with a history of ten miscarriages. Am J Reprod Immunol 2000; 44:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/28\">",
"      Clark DA, Coulam CB, Stricker RB. Is intravenous immunoglobulins (IVIG) efficacious in early pregnancy failure? A critical review and meta-analysis for patients who fail in vitro fertilization and embryo transfer (IVF). J Assist Reprod Genet 2006; 23:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/29\">",
"      Ata B, Tan SL, Shehata F, et al. A systematic review of intravenous immunoglobulin for treatment of unexplained recurrent miscarriage. Fertil Steril 2011; 95:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/30\">",
"      Marqusee E, Hill JA, Mandel SJ. Thyroiditis after pregnancy loss. J Clin Endocrinol Metab 1997; 82:2455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/31\">",
"      Negro R, Formoso G, Mangieri T, et al. Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications. J Clin Endocrinol Metab 2006; 91:2587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/32\">",
"      Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002; 17:2858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/33\">",
"      Hirahara F, Andoh N, Sawai K, et al. Hyperprolactinemic recurrent miscarriage and results of randomized bromocriptine treatment trials. Fertil Steril 1998; 70:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/34\">",
"      Scott JR. Recurrent miscarriage: overview and recommendations. Clin Obstet Gynecol 1994; 37:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/35\">",
"      Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Syst Rev 2008; :CD003511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/36\">",
"      Coomarasamy A, Truchanowicz EG, Rai R. Does first trimester progesterone prophylaxis increase the live birth rate in women with unexplained recurrent miscarriages? BMJ 2011; 342:d1914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/37\">",
"      Choi BC, Polgar K, Xiao L, Hill JA. Progesterone inhibits in-vitro embryotoxic Th1 cytokine production to trophoblast in women with recurrent pregnancy loss. Hum Reprod 2000; 15 Suppl 1:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/38\">",
"      Kaandorp SP, Goddijn M, van der Post JA, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010; 362:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/39\">",
"      Clark P, Walker ID, Langhorne P, et al. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood 2010; 115:4162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/40\">",
"      Scott JR, Pattison N. Human chorionic gonadotrophin for recurrent miscarriage. Cochrane Database Syst Rev 2000; :CD000101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/41\">",
"      Li TC, Ding SH, Anstie B, et al. Use of human menopausal gonadotropins in the treatment of endometrial defects associated with recurrent miscarriage: preliminary report. Fertil Steril 2001; 75:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/42\">",
"      Bohnet HG, Kato K, Trapp M, et al. Different hormonal patterns in human menopausal gonadotropin-treated, clomiphene citrate-treated, and untreated conception cycles. Fertil Steril 1986; 45:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/43\">",
"      Huang KE. The primary treatment of luteal phase inadequacy: progesterone versus clomiphene citrate. Am J Obstet Gynecol 1986; 155:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/44\">",
"      Murray DL, Reich L, Adashi EY. Oral clomiphene citrate and vaginal progesterone suppositories in the treatment of luteal phase dysfunction: a comparative study. Fertil Steril 1989; 51:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/45\">",
"      Balasch J, Creus M, Fabregues F, et al. In-vitro fertilization treatment for unexplained recurrent abortion: a pilot study. Hum Reprod 1996; 11:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/46\">",
"      Pellicer A, Rubio C, Vidal F, et al. In vitro fertilization plus preimplantation genetic diagnosis in patients with recurrent miscarriage: an analysis of chromosome abnormalities in human preimplantation embryos. Fertil Steril 1999; 71:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/47\">",
"      Sim&oacute;n C, Rubio C, Vidal F, et al. Increased chromosome abnormalities in human preimplantation embryos after in-vitro fertilization in patients with recurrent miscarriage. Reprod Fertil Dev 1998; 10:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/48\">",
"      Raziel A, Herman A, Strassburger D, et al. The outcome of in vitro fertilization in unexplained habitual aborters concurrent with secondary infertility. Fertil Steril 1997; 67:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/49\">",
"      Hassold TJ. A cytogenetic study of repeated spontaneous abortions. Am J Hum Genet 1980; 32:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/50\">",
"      Remoh&iacute; J, Gallardo E, Levy M, et al. Oocyte donation in women with recurrent pregnancy loss. Hum Reprod 1996; 11:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/51\">",
"      Tempfer CB, Kurz C, Bentz EK, et al. A combination treatment of prednisone, aspirin, folate, and progesterone in women with idiopathic recurrent miscarriage: a matched-pair study. Fertil Steril 2006; 86:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/52\">",
"      Lund M, Kamper-J&oslash;rgensen M, Nielsen HS, et al. Prognosis for live birth in women with recurrent miscarriage: what is the best measure of success? Obstet Gynecol 2012; 119:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/53\">",
"      Brigham SA, Conlon C, Farquharson RG. A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage. Hum Reprod 1999; 14:2868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/54\">",
"      Bricker L, Farquharson RG. Types of pregnancy loss in recurrent miscarriage: implications for research and clinical practice. Hum Reprod 2002; 17:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/55\">",
"      Goldenberg RL, Mayberry SK, Copper RL, et al. Pregnancy outcome following a second-trimester loss. Obstet Gynecol 1993; 81:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/56\">",
"      Edlow AG, Srinivas SK, Elovitz MA. Second-trimester loss and subsequent pregnancy outcomes: What is the real risk? Am J Obstet Gynecol 2007; 197:581.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37976/abstract/57\">",
"      Jivraj S, Anstie B, Cheong YC, et al. Obstetric and neonatal outcome in women with a history of recurrent miscarriage: a cohort study. Hum Reprod 2001; 16:102.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5444 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-4F5D24ED7D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_5_37976=[""].join("\n");
var outline_f37_5_37976=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PARENTAL KARYOTYPE ABNORMALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      UTERINE ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANTIPHOSPHOLIPID SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SUSPECTED IMMUNOLOGIC DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      THYROID DYSFUNCTION AND DIABETES MELLITUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      POLYCYSTIC OVARY SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HYPERPROLACTINEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      THROMBOPHILIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      UNEXPLAINED RPL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Lifestyle modification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Progesterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Aspirin with or without heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Human chorionic gonadotropin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Human menopausal gonadotropin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Clomiphene citrate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      In vitro fertilization and preimplantation genetic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Gestational carrier",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Oocyte donation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      FUTURE PREGNANCY PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26414623\">",
"      Continued pregnancy loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26414616\">",
"      Other obstetric issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4457?source=related_link\">",
"      Cervical insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18167?source=related_link\">",
"      Chromosomal translocations, deletions, and inversions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/6/8298?source=related_link\">",
"      Definition and etiology of recurrent pregnancy loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26679?source=related_link\">",
"      Evaluation of couples with recurrent pregnancy loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26101?source=related_link\">",
"      Intrauterine adhesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/0/44041?source=related_link\">",
"      Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16826?source=related_link\">",
"      Metformin for treatment of the polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24807?source=related_link\">",
"      Oocyte donation for assisted reproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11482?source=related_link\">",
"      Optimizing natural fertility in couples planning pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16186?source=related_link\">",
"      Overview of thyroid disease in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/62/20450?source=related_link\">",
"      Patient information: Repeated miscarriage (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23431?source=related_link\">",
"      Preimplantation genetic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30662?source=related_link\">",
"      Reproductive issues in women with uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3850?source=related_link\">",
"      Subclinical hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/21/29014?source=related_link\">",
"      Surgical management of congenital uterine anomalies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15015?source=related_link\">",
"      Surrogate pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32532?source=related_link\">",
"      Transabdominal cervical cerclage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/42/37544?source=related_link\">",
"      Transvaginal cervical cerclage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21143?source=related_link\">",
"      Treatment of Graves' hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31561?source=related_link\">",
"      Treatment of hyperprolactinemia due to lactotroph adenoma and other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_5_37977="Risk factors for cardiovascular disease in the renal transplant recipient";
var content_f37_5_37977=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Risk factors for cardiovascular disease in the renal transplant recipient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/5/37977/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/5/37977/contributors\">",
"     John Vella, MD, FACP, FRCP, FASN",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/5/37977/contributors\">",
"     Krista L Lentine, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/5/37977/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/5/37977/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/5/37977/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/5/37977/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/5/37977/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular disease is a leading cause of morbidity and mortality after kidney transplantation. Death from cardiovascular disease is also the most common cause of graft loss.",
"   </p>",
"   <p>",
"    This topic reviews the risk factors of cardiovascular disease among renal transplant recipients. The epidemiology of cardiovascular disease following transplantation, cardiovascular outcomes compared with dialysis patients and the evaluation of renal transplant candidates are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17992?source=see_link\">",
"     \"Patient survival after renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/55/26490?source=see_link\">",
"     \"Evaluation of the potential renal transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW OF CARDIOVASCULAR RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplant recipients have a lower risk of fatal and non-fatal cardiovascular events compared with wait-listed patients on dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/1-4\">",
"     1-4",
"    </a>",
"    ], but a much higher risk compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/5\">",
"     5",
"    </a>",
"    ]. Fifty to 60 percent of post-transplant deaths are directly attributable to cardiovascular disease, with an incidence of ischemic heart disease of approximately one per 100 person years at risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Cardiovascular disease is the most common cause of death with graft function after transplant, and accounts for 30 percent of graft loss from death overall, with the greatest rates early after transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The high rate of cardiovascular deaths in the transplant population is due in part to the large number of diabetic patients in the end-stage renal disease (ESRD) population, who are at markedly increased cardiovascular risk compared with non-diabetic transplant recipients. As an example, in one study of 933 transplant recipients, cardiovascular disease was the most common cause of death among diabetic recipients; in contrast, most deaths among nondiabetic recipients were due to infection, malignancy or other causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However the cardiovascular risk among transplant recipients who do not have ESRD related to diabetes is still higher than in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/8\">",
"     8",
"    </a>",
"    ]. The increased cardiovascular risk is due to the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An exacerbation of traditional risk factors present in the general population by immunosuppressive drugs. (",
"      <a class=\"graphic graphic_figure graphicRef51988 \" href=\"mobipreview.htm?38/8/39054\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Non-traditional risk factors related to immunosuppressive agents or to chronic kidney disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Traditional risk factors for coronary heart disease after renal transplantation were investigated in a report of 403 patients who received 464 kidney transplants during a ten-year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/10\">",
"     10",
"    </a>",
"    ]. New atherosclerotic complications developed in 16 percent of patients. After accounting for pre-transplant vascular disease, multivariate analysis revealed that the following risk factors were independently associated with post-transplant atherosclerotic cardiovascular disease:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increasing patient age",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Male sex",
"     </li>",
"     <li>",
"      Cigarette smoking",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Elevated serum cholesterol",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were observed in other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nontraditional risk factors that have been associated with increased cardiovascular risk in various studies include reduced kidney function following transplantation, dialysis vintage prior to transplantation, rejection, hyperhomocysteinemia, elevated levels of lipoprotein(a), elevated C-reactive protein and interleukin-6 levels, proteinuria, and low levels of physical activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/14-21\">",
"     14-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although not directly linked to cardiovascular disease, the presence of vascular calcifications detected radiographically prior to transplantation (a common finding) is also associated with increased cardiovascular and all-cause mortality post-transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17738?source=see_link\">",
"     \"Vascular calcification in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individual risk factors are discussed below. (See",
"    <a class=\"local\" href=\"#H44613340\">",
"     'Individual risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H275228\">",
"    <span class=\"h2\">",
"     Myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have described the incidence and risk factors for myocardial infarction among renal transplant recipients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study based upon the United States Renal Data System (USRDS) evaluated the clinical correlates of post-transplant myocardial infarction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/1\">",
"       1",
"      </a>",
"      ]. Among nearly 36,000 patients, the incidence of MI at 6, 12, and, 36 months was 4.3, 5.2, and 11.1 percent, respectively. The principal risk factors were increased age, recipient of kidneys from older and deceased donors, delayed allograft function, and the presence of pre-transplant comorbidities, including diabetes, angina, peripheral vascular disease, and myocardial infarction. The diagnosis of post-transplant diabetes and the development of allograft failure were also significantly associated with the development of an MI.",
"     </li>",
"     <li>",
"      In a similar study of 53,297 patients, a markedly increased risk of acute myocardial infarction was observed early after transplantation, less than three months post-surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/24\">",
"       24",
"      </a>",
"      ]. Compared with waitlist patients, the risk also varied by recipients of a deceased donor kidney (RR 3.57, 95% CI 3.21-3.96) and living donor kidney (RR 2.81, 95% CI 2.31-3.42).",
"     </li>",
"     <li>",
"      In a retrospective analysis of the placebo arm of the Assessment of LEscol in Renal Transplantation (ALERT) study, independent risk factors for non-fatal myocardial infarction by multivariate analysis were preexisting coronary heart disease (hazard ratio, 3.69), total cholesterol level (HR, 1.55 per 50",
"      <span class=\"nowrap\">",
"       mg/dL),",
"      </span>",
"      and prior acute rejection (HR, 2.36) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/12\">",
"       12",
"      </a>",
"      ]. Age, diabetes, ST-T changes, and elevated serum creatinine levels were independent risk factors for cardiac death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274573\">",
"    <span class=\"h2\">",
"     Prediction of cardiovascular risk",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274580\">",
"    <span class=\"h3\">",
"     Framingham risk score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Framingham risk score is a composite index designed to predict coronary heart disease in the general population based on traditional risk factors of age, gender, cholesterol levels, hypertension, and diabetes status. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=see_link&amp;anchor=H9#H9\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\", section on 'Framingham risk scores'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the Framingham risk score performs well in the general population, it generally underestimates the risk of cardiovascular events among kidney transplant patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/14,25\">",
"     14,25",
"    </a>",
"    ]. The individual Framingham risk factors are significantly associated with cardiovascular risk among kidney transplant recipients, but some effect sizes are increased among such patients.",
"   </p>",
"   <p>",
"    This prediction error is greatest among patients at highest risk, and is driven in part by an underestimate of diabetes-related risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/14,25\">",
"     14,25",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of 1124 kidney transplant recipients with stable graft function at one year, the observed increase in risk conferred by diabetes was greater in transplant recipients compared with the Framingham Heart Study population (hazard ratios of 2.8 versus 1.5 respectively, among men, and 5.4 versus 1.8, respectively, among women) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/25\">",
"       25",
"      </a>",
"      ]. The risks conferred by age and smoking were also underestimated by the Framingham risk score, though to a lesser extent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a historical cohort study of transplant recipients with functional allografts at one year, the Framingham risk score predicted only 59 percent of observed coronary events [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/14\">",
"       14",
"      </a>",
"      ]. This was entirely due to an underestimate among high risk patients (defined as greater than 20 percent risk of event at ten years according to the Framingham heart score). The risk score performed well among low risk patients (less than 20 percent risk at ten years).",
"     </li>",
"     <li>",
"      In a prospective cohort study of 540 transplant recipients, the Framingham risk score underestimated cardiac events but not stroke, with ratios of observed-to-predicted cardiac events of 1.64 and 0.96, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/26\">",
"       26",
"      </a>",
"      ]. As noted in the previous study, the risk score performed least well among the highest risk patients; subgroup analysis showed higher observed-to-predicted cardiac event ratios among patients with pretransplant diabetes, prior cardiac disease or both (2.12; 2.00; 2.74, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274587\">",
"    <span class=\"h3\">",
"     Biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of biomarkers such as cardiac troponins may allow more accurate cardiovascular risk stratification than is provided by currently available methods. Persistent elevations in cardiac troponins may result from volume overload, uncontrolled hypertension or left ventricular hypertrophy, all which confer a higher risk of cardiovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/27\">",
"     27",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    As an example, in a single-center retrospective cohort study, elevated troponin T concentrations prior to transplantation were independently associated with post-transplantation cardiac events and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/28\">",
"     28",
"    </a>",
"    ]. Over a mean follow-up of 28 months, troponin T concentrations of 0.01 to 0.03, 0.04 to 0.1, and greater than 0.10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    were associated with increased relative risks of major adverse cardiac events after transplantation (hazard ratios of 2.52, 4.48 and 6.12, respectively).",
"   </p>",
"   <p>",
"    In a prospective observational study of 331 kidney or kidney-pancreas recipients, each 0.01",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    increase in troponin I measured at the time of transplantation was associated on multivariate analysis with a 17 percent increase in the risk of major adverse cardiac events within three months after transplantation (adjusted OR 1.17) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It remains uncertain how biomarker assessment should be used to direct therapies or subsequent diagnostic testing before or after kidney transplantation. Measurement of cardiac troponin concentrations in transplant recipients may be considered as an additional prognostic marker.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274267\">",
"    <span class=\"h2\">",
"     Congestive heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular disease includes both ischemic coronary artery disease and cardiomyopathy. Patients with ESRD, including transplant recipients, are at higher risk for both compared to the general population. Cardiac end points are often pooled in epidemiologic studies, with the presumption that all reflect ischemic atherosclerotic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/5\">",
"     5",
"    </a>",
"    ]. Some studies have examined the risk of specific cardiac endpoints among transplant recipients.",
"   </p>",
"   <p>",
"    Studies have shown that cardiomyopathy, either with or without clinical heart failure, is common among kidney transplant recipients. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective analysis of data derived from the USRDS showed that the cumulative incidence of new onset CHF was 10.2 and 18.3 percent at 12 and 36 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective study of 638 consecutive renal transplant recipients who were free of cardiac disease at one year, new onset CHF occurred as frequently as new onset ischemic heart disease (1.26 versus 1.22",
"      <span class=\"nowrap\">",
"       events/100",
"      </span>",
"      patient-years, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The USRDS reports that CHF is second only to infection as a cause of hospitalization after kidney transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Independent risk factors for new onset CHF after transplantation include age, diabetes, anemia, and hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/4,15\">",
"     4,15",
"    </a>",
"    ]. Studies of USRDS data have identified obesity, donor factors that may predict sub-optimal graft function, and graft loss as risk factors for CHF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/4,31\">",
"     4,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Obesity and smoking are associated with increased the risk of CHF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/4,32\">",
"     4,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BMI was independently associated with CHF in several USRDS registry studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/4,33,34\">",
"     4,33,34",
"    </a>",
"    ]. In one study, BMI greater than or equal to 30 predicted up to 59 percent relative risk increase compared to BMI less than 30 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/33\">",
"     33",
"    </a>",
"    ]. In another study of USRDS data, BMI greater than 28.3 independently predicted a 57 percent relative increase in the risk of hospitalized CHF compared with lower BMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CHF is associated with increased mortality after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/4,35\">",
"     4,35",
"    </a>",
"    ]. In a single center study, left ventricular systolic dysfunction, defined as left ventricular ejection fraction less than or equal to 45 percent by gated single photon emission computed tomography at the time of transplantation, was associated with 4.8 times the risk of cardiac death, 2 times the risk of all-cause mortality, and 1.8 times the risk of cardiac complications compared with normal cardiac function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/35\">",
"     35",
"    </a>",
"    ]. A study of USRDS data identified clinical diagnosis of new-onset heart failure after transplant as a potent predictor of subsequent death (adjusted HR 2.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44613340\">",
"    <span class=\"h1\">",
"     INDIVIDUAL RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3548021\">",
"    <span class=\"h2\">",
"     Pre-transplant cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pre-transplant cardiovascular disease is the most important predictor of post-transplant cardiovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/10,36\">",
"     10,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dyslipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite advances in short-term allograft survival due to improvements in immunosuppressive regimens, dyslipidemia remains a significant problem in the transplant population. Corticosteroids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , rapamycin, and to a lesser extent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    increase serum triglyceride and cholesterol concentrations. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29546?source=see_link\">",
"     \"Lipid abnormalities after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is a well-known risk factor for cardiovascular disease and stroke in both the general population and transplant recipients, due in part to its association with left ventricular hypertrophy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37685?source=see_link\">",
"     \"Cardiovascular risks of hypertension\"",
"    </a>",
"    .) A decline in long-term allograft and patient survival is associated with the development of post-transplant hypertension.",
"   </p>",
"   <p>",
"    The immunosuppressive agents that can cause new onset hypertension or exacerbate preexisting hypertension include calcineurin inhibitors and, to a lesser extent, because of rapid dose reduction, corticosteroids.",
"   </p>",
"   <p>",
"    Details concerning these issues and the management of hypertension in kidney transplant recipients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16761?source=see_link\">",
"     \"Hypertension after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both pretransplant diabetes and new-onset diabetes after transplant are associated with the risk of post-transplant cardiovascular complications such as myocardial infarction and heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Antirejection medications that contribute to NODAT include glucocorticoids, calcineurin inhibitors, and MTOR inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/40/26250?source=see_link\">",
"     \"New onset diabetes after transplant (NODAT) in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As observed among non-transplanted patients, renal insufficiency in renal transplant patients is a significant risk factor for adverse cardiovascular outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/20,33,37\">",
"     20,33,37",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among nearly 60,000 patients in one registry study, there was a graded increase in the risk of cardiac death with serum creatinine levels above 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (133",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      at one year post-transplant, up to more than twice the relative risk among those with serum creatinine levels 2.6 to 4.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      compared with &lt;1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (adjusted HR 2.6) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second registry study of almost 30,000 renal transplant recipients, a decreased estimated glomerular filtration rate &lt;45",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      at one year post-transplant correlated with increased risk of acute coronary syndrome (adjusted HR 2.2) and heart failure (adjusted HR 2.95) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among over 1000 placebo-treated patients in the Assessment of LEscol in Renal Transplantation (ALERT) trial, an increased serum creatinine concentration, particularly higher than 2.3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (200",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      was strongly associated with an increased risk of adverse cardiac events and cardiac death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/37,38\">",
"       37,38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44627677\">",
"    <span class=\"h2\">",
"     Dialysis vintage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing dialysis vintage prior to transplantation is associated with a graded increase in the risk of cardiovascular death after transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/20\">",
"     20",
"    </a>",
"    ]. A likely explanation for this is that accelerated atherogenesis is observed as part of the uremic syndrome. Pro-atherogenic factors that contribute to the progression of vascular disease prior to transplantation may include hyperhomocysteinemia, hyperfibrinogenemia, increased calcium ingestion, abnormalities of mineral metabolism, dyslipidemia, and modification of low-density lipoproteins (LDL) by advanced glycosylation end-products (AGE), particularly in diabetic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These factors become increasingly important with the onset of chronic allograft dysfunction that leads to progressive uremia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14170?source=see_link\">",
"     \"Risk factors for graft failure in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4028198\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia defined by WHO criteria affects up to 30 to 40 percent of kidney transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Post-transplant anemia has been correlated with the risk of subsequent cardiovascular complications such as heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/4\">",
"     4",
"    </a>",
"    ] and atrial fibrillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/44\">",
"     44",
"    </a>",
"    ] as well as with increased risk of post-transplant graft loss and patient death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations regarding the management of post-transplant anemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/29/41433?source=see_link\">",
"     \"Anemia and the renal transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Obesity and metabolic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemic of obesity in the United States has not spared kidney transplant candidates. Obesity trends in transplant recipients tend to mimic the general population. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/20/12615?source=see_link\">",
"     \"Screening for and clinical evaluation of obesity in adults\"",
"    </a>",
"    .) In one study using data from the United Network for Organ Sharing, among 27,372 individuals who underwent kidney transplantation between 1997 and 1999, 20 percent were obese (BMI 30 to 35) or morbidly obese (BMI &ge;35), and an additional 30 percent were classified as overweight (BMI 25 to 29) though not obese [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Weight gain after transplant is common, and may be related to improved appetite with reversal of uremia and relatively high steroid doses in the peri-transplant period, but is also associated with physical inactivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/48\">",
"     48",
"    </a>",
"    ]. Obesity among transplant recipients is frequently associated with the metabolic syndrome. The metabolic syndrome was identified among 63 percent of 606 prevalent renal transplant recipients assessed at a median of six years post-transplant at one center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Obesity increases the risk of cardiovascular disease in the general population. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/35/3641?source=see_link\">",
"     \"Obesity, weight reduction, and cardiovascular disease\"",
"    </a>",
"    .) Among kidney transplant recipients, the presence of obesity, particularly in association with the metabolic syndrome, also appears to be associated with an increased number of adverse cardiovascular events. In one study of 337 renal transplant recipients, one-third had metabolic syndrome by the first transplant anniversary, whereas only 20 percent had metabolic syndrome before transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/50\">",
"     50",
"    </a>",
"    ]. Over eight years of followup, 42 percent of the sample developed atherosclerotic disease events, and the risk of these events was significantly increased among patients with metabolic syndrome by one year after transplant (hazard ratio 3.4, 95% CI 1.6-7.3).",
"   </p>",
"   <p>",
"    High BMI has also been associated with an increased risk of cardiac death after kidney transplantation. In a study of nearly 52,000 patients in the USRDS registry, the adjusted risk of cardiac death increased at both low BMI (adjusted hazard ratio (HR) 1.3 for BMI &lt;20) and high BMI (adjusted HR 1.2 for BMI 30 to 32; adjusted HR 1.4 for BMI &gt;36) compared with the reference group with BMI 22 to 24 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Obesity also increases the risk of heart failure and atrial fibrillation. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a single center study, the five-year incidence of cardiac diagnoses increased from 9 to 30 percent as the BMI quartiles increased from the lowest to highest [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/32\">",
"       32",
"      </a>",
"      ]. This was largely due to increases in the incidence of heart failure and atrial fibrillation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    BMI was independently associated with increased risk of CHF and atrial fibrillation in several USRDS registry studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/4,33,34\">",
"     4,33,34",
"    </a>",
"    ]. As an example, BMI greater than or equal to 30 predicted up to 59 percent relative risk increase compared with BMI less than 30 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/33\">",
"     33",
"    </a>",
"    ]. In other studies of USRDS data, BMI greater than 28 independently predicted a 57 and 79 percent relative increases in the risk of hospitalized CHF and AF, respectively, compared with lower BMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/31,34\">",
"     31,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lifestyle changes based in diet and exercise, with supervision by a renal dietician as needed, are first-line strategies to achieve and maintain normal body weight among obese transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/52\">",
"     52",
"    </a>",
"    ]. Cases of bariatric surgery among morbidly obese transplant recipients have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/53\">",
"     53",
"    </a>",
"    ], but surgical therapies warrant prospective evaluation to quantify risks and benefits in this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the general and transplant population, smoking increases the risk of cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Among transplant recipients, smoking has been independently associated with the risk of death with graft function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/55\">",
"     55",
"    </a>",
"    ] and with events such as heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/4\">",
"     4",
"    </a>",
"    ] and ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/3\">",
"     3",
"    </a>",
"    ]. With smoking cessation, the increased risk dissipates over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/54\">",
"     54",
"    </a>",
"    ]. We recommend complete smoking cessation, with the adoption of measures to encourage smoking cessation.",
"   </p>",
"   <p>",
"    Unfortunately, no clinical trial data address the safety and utility of pharmacologic interventions to promote smoking cessation in the transplant population:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nicotine replacement options probably carry little risk and may promote successful cessation.",
"     </li>",
"     <li>",
"      The use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/2/15398?source=see_link\">",
"       varenicline",
"      </a>",
"      (Chantix&reg;, Pfizer) may be problematic in kidney allograft recipients with poor kidney function, as this drug is renally excreted. Dosing of this agent in those with decreased kidney function is discussed separately. (See",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/2/15398?source=see_link\">",
"       \"Varenicline: Drug information\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44627329\">",
"    <span class=\"h2\">",
"     Homocysteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homocysteine is a nonessential amino acid that is an intermediate in the synthesis of cysteine and a precursor of the essential amino acid, methionine. Since homocysteine is normally cleared by the kidneys, serum concentrations are increased in chronic renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Hyperhomocysteinemia is also caused by an absolute or relative deficiency of vitamins B6, B12, and folate, all of which are involved in methionine metabolism and by defects in the methylene tetrahydrofolate reductase enzyme. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of elevated homocysteine levels in peripheral venous blood has been identified as an independent risk factor for ischemic heart disease and stroke in the general population, as well as being a predictor of mortality in patients with coronary heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of homocysteine\", section on 'Role in vascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This association has also been found among renal transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/14,60,61\">",
"     14,60,61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one prospective study of 207 stable patients, fasting mean total homocysteine levels were significantly higher among patients who experienced a cardiovascular event at follow-up of 21 months (32 versus 18",
"      <span class=\"nowrap\">",
"       &micro;mol/L",
"      </span>",
"      for those without such an event) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 733 kidney transplant recipients during a six-year period, elevated homocysteine levels were associated with 2.44 times the mortality risk of patients with normal levels (hazard ratio 2.44, CI 95% 1.45-4.12) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with ESRD, hyperhomocysteinemia is closely linked with decreased serum folate and pyridoxine (vitamin B6) concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/57\">",
"     57",
"    </a>",
"    ]. Serum homocysteine concentrations often continue to rise after both renal and cardiac transplantation, independent of renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. In one series, serum concentrations of total homocysteine were significantly higher in 120 renal transplant recipients than in 60 healthy controls (mean 19.0 versus 11.6",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    or 53 patients with chronic renal failure (mean 16.0",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/64\">",
"     64",
"    </a>",
"    ]. In this report, renal transplant recipients on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    had significantly higher plasma homocysteine concentrations than those not on cyclosporine. A similar role for cyclosporine was noted in another series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/65\">",
"     65",
"    </a>",
"    ]; however, this association has not been confirmed in other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Effective reduction in serum homocysteine levels in renal transplant recipients may be obtained with the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    and vitamins B6 and B12 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/67\">",
"     67",
"    </a>",
"    ]. However, although hyperhomocysteinemia is an independent risk factor for cerebrovascular, peripheral vascular, and coronary heart disease, lowering homocysteine levels has not been shown to decrease cardiovascular risk in renal transplant recipients. As an example, an NIH-sponsored multicenter randomized trial showed no reduction in all-cause mortality, ESRD, or in a composite outcome including cardiovascular death, myocardial infarction, resuscitated sudden death, stroke, revascularization, amputation or aortic aneurysm repair, among 4110 renal transplant recipients treated with vitamin B6 and vitamin B12 and with either high or low dose folic acid, despite the fact that homocysteine was effectively lowered with high dose folic acid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H240914\">",
"    <span class=\"h2\">",
"     Right heart failure and pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Right heart failure and pulmonary hypertension at the time of transplantation have been associated with both delayed graft function and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. In a study of 215 potential renal transplant candidates, estimated right ventricular systolic pressure &ge;50 mmHg was associated with an increased risk of post transplant death (hazard ratio 3.75) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/70\">",
"     70",
"    </a>",
"    ]. Dialysis vintage was the strongest correlate of an elevated PASP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3548087\">",
"    <span class=\"h1\">",
"     RISK REDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reduction of cardiovascular risk requires the accurate assessment of risk in transplant candidates and the appropriate pharmacologic and nonpharmacologic interventions. (See",
"    <a class=\"local\" href=\"#H44613340\">",
"     'Individual risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4028523\">",
"    <span class=\"h2\">",
"     Use of cardiovascular medications among kidney transplant recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reduction in cardiovascular risk may be achieved through appropriate medical therapies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=see_link\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28570?source=see_link\">",
"     \"Determinants and management of cardiovascular risk in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is considerable practice variation in the use of potentially cardioprotective medications in kidney transplant recipients even among patients considered to be at high risk based on preexisting diabetes or cardiovascular disease. Studies suggest that primary and secondary cardiovascular preventive measures are underutilized among transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Long-Term Deterioration of Kidney Allograft Function (DeKAF) study, a multicenter prospective observational study of transplant recipients revealed that fewer than 30 percent of participating transplant recipients with pre-existing cardiovascular disease or diabetes received",
"      <span class=\"nowrap\">",
"       ACE-inhibitors/angiotensin-II",
"      </span>",
"      receptor blockers therapy at six months posttransplant; fewer than 60 percent received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ; and half received a statin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/71\">",
"       71",
"      </a>",
"      ].",
"      <br/>",
"     </li>",
"     <li>",
"      Predicting Outcomes in Renal Transplantation (PORT), a multi-center collaborative database investigation of non-immunosuppressive medication use found no difference in the use of most cardiovascular medications between diabetic and nondiabetic patients. Although the use of multiple cardiovascular medications was higher in patients with a previous cardiovascular event compared with patients with no previous cardiovascular disease, fewer than 75 percent of patients with previous cardiovascular disease were using a statin or antiplatelet agent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Use of integrated Organ Procurement and Transplantation Network (OPTN) registry and pharmacy billing claims data to characterize cardiovascular medication prescriptions early after myocardial infarction showed that within the first 60 days after AMI, prescriptions for beta-blockers, anti-platelet agents,",
"      <span class=\"nowrap\">",
"       ACE-inhibitors/angiotensin-II",
"      </span>",
"      receptor blockers and statins were submitted, respectively, in only 83, 48, 65, and 72 percent, which was roughly comparable to non-transplant patients matched by demographic and measured clinical characteristics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37977/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While there may be legitimate reasons for not prescribing potentially cardioprotective medications in transplanted patients (eg, allograft dysfunction, hyperkalemia and anemia may limit use of",
"    <span class=\"nowrap\">",
"     ACE-inhibitors/angiotensin-II",
"    </span>",
"    receptor blockers), these studies suggest potential room for improvement in the treatment of cardiovascular risks improved among high risk transplant recipients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiovascular disease is the leading cause of death among kidney transplant recipients. Death from cardiovascular disease is also the most common cause of graft loss. Transplant recipients have a lower risk of cardiovascular events compared with wait-listed patients on dialysis, but a much higher risk compared with the general population. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Framingham risk score underestimates the risk of cardiovascular events among kidney transplant patients. Although the individual Framingham risk factors are significantly associated with cardiovascular risk among kidney transplant recipients, the effect sizes are increased among such patients, especially among patients at highest risk. (See",
"      <a class=\"local\" href=\"#H274580\">",
"       'Framingham risk score'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Traditional risk factors present in the general population also exist in renal transplant recipients. These factors may be exacerbated by immunosuppressive medications. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Overview of cardiovascular risk'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H44613340\">",
"       'Individual risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dyslipidemia remains a significant problem in the transplant population. Corticosteroids,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , rapamycin, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      elevate serum triglyceride and cholesterol concentrations. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Dyslipidemia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29546?source=see_link\">",
"       \"Lipid abnormalities after renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypertension is caused or worsened by calcineurin inhibitors and, to a lesser extent because of rapid dose reduction, corticosteroids. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Hypertension'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16761?source=see_link\">",
"       \"Hypertension after renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Both pretransplant diabetes and new-onset diabetes after transplant are associated with the risk of post-transplant cardiovascular complications such as myocardial infarction and heart failure. Antirejection medications that contribute to NODAT include glucocorticoids, calcineurin inhibitors, and MTOR inhibitors. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diabetes mellitus'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/40/26250?source=see_link\">",
"       \"New onset diabetes after transplant (NODAT) in renal transplant recipients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reduced renal function after transplantation and dialysis vintage prior to transplantation are significant cardiovascular risk factors after transplantation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Chronic kidney disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link\">",
"       \"Chronic kidney disease and coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the general and transplant population, smoking increases the risk of cardiovascular disease. With smoking cessation, the increased risk dissipates over time. Among all transplant recipients, we recommend complete smoking cessation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Smoking'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/34997?source=see_link\">",
"       \"Patterns of tobacco use\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiomyopathy, either with or without clinical heart failure, is common among kidney transplant recipients, and is associated with mortality. Congestive heart failure (CHF) is second only to infection as a cause of hospitalization after kidney transplantation. Risk factors for CHF after transplantation include age, diabetes, anemia and hypertension and decreased graft function. (See",
"      <a class=\"local\" href=\"#H274267\">",
"       'Congestive heart failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary and secondary measures to prevent cardiovascular events are underutilized in transplant recipients. (See",
"      <a class=\"local\" href=\"#H4028523\">",
"       'Use of cardiovascular medications among kidney transplant recipients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/1\">",
"      Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005; 16:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/2\">",
"      Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 2004; 4:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/3\">",
"      Lentine KL, Rocca Rey LA, Kolli S, et al. Variations in the risk for cerebrovascular events after kidney transplant compared with experience on the waiting list and after graft failure. Clin J Am Soc Nephrol 2008; 3:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/4\">",
"      Lentine KL, Schnitzler MA, Abbott KC, et al. De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications. Am J Kidney Dis 2005; 46:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/5\">",
"      Jardine AG, Gaston RS, Fellstrom BC, Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet 2011; 378:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/6\">",
"      Yeo FE, Villines TC, Bucci JR, et al. Cardiovascular risk in stage 4 and 5 nephropathy. Adv Chronic Kidney Dis 2004; 11:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/7\">",
"      Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006; 82:603.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Renal Data System, USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/9\">",
"      Cosio FG, Hickson LJ, Griffin MD, et al. Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes. Am J Transplant 2008; 8:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/10\">",
"      Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 1988; 84:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/11\">",
"      de Mattos AM, Prather J, Olyaei AJ, et al. Cardiovascular events following renal transplantation: role of traditional and transplant-specific risk factors. Kidney Int 2006; 70:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/12\">",
"      Jardine AG, Fellstr&ouml;m B, Logan JO, et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. Am J Kidney Dis 2005; 46:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/13\">",
"      Vanrenterghem YF, Claes K, Montagnino G, et al. Risk factors for cardiovascular events after successful renal transplantation. Transplantation 2008; 85:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/14\">",
"      Ducloux D, Kazory A, Chalopin JM. Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int 2004; 66:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/15\">",
"      Rigatto C, Parfrey P, Foley R, et al. Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol 2002; 13:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/16\">",
"      Abbott KC, Bucci JR, Cruess D, et al. Graft loss and acute coronary syndromes after renal transplantation in the United States. J Am Soc Nephrol 2002; 13:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/17\">",
"      Jindal RM, Zawada ET Jr. Obesity and kidney transplantation. Am J Kidney Dis 2004; 43:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/18\">",
"      Dussol B, Bonnet JL, Sampol J, et al. Prognostic value of inducible myocardial ischemia in predicting cardiovascular events after renal transplantation. Kidney Int 2004; 66:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/19\">",
"      Abedini S, Holme I, M&auml;rz W, et al. Inflammation in renal transplantation. Clin J Am Soc Nephrol 2009; 4:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/20\">",
"      Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/21\">",
"      Zelle DM, Corpeleijn E, Stolk RP, et al. Low physical activity and risk of cardiovascular and all-cause mortality in renal transplant recipients. Clin J Am Soc Nephrol 2011; 6:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/22\">",
"      Rosas SE, Mensah K, Weinstein RB, et al. Coronary artery calcification in renal transplant recipients. Am J Transplant 2005; 5:1942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/23\">",
"      Hern&aacute;ndez D, Rufino M, Bartolomei S, et al. Clinical impact of preexisting vascular calcifications on mortality after renal transplantation. Kidney Int 2005; 67:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/24\">",
"      Kasiske BL, Maclean JR, Snyder JJ. Acute myocardial infarction and kidney transplantation. J Am Soc Nephrol 2006; 17:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/25\">",
"      Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/26\">",
"      Kiberd B, Panek R. Cardiovascular outcomes in the outpatient kidney transplant clinic: the Framingham risk score revisited. Clin J Am Soc Nephrol 2008; 3:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/27\">",
"      Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol 2006; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/28\">",
"      Hickson LT, El-Zoghby ZM, Lorenz EC, et al. Patient survival after kidney transplantation: relationship to pretransplant cardiac troponin T levels. Am J Transplant 2009; 9:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/29\">",
"      Claes K, Bammens B, Evenepoel P, et al. Troponin I is a predictor of acute cardiac events in the immediate postoperative renal transplant period. Transplantation 2010; 89:341.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Renal Data System, USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/31\">",
"      Abbott KC, Hypolite IO, Hshieh P, et al. Hospitalized congestive heart failure after renal transplantation in the United States. Ann Epidemiol 2002; 12:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/32\">",
"      Lentine KL, Rocca-Rey LA, Bacchi G, et al. Obesity and cardiac risk after kidney transplantation: experience at one center and comprehensive literature review. Transplantation 2008; 86:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/33\">",
"      Abbott KC, Yuan CM, Taylor AJ, et al. Early renal insufficiency and hospitalized heart disease after renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003; 14:2358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/34\">",
"      Abbott KC, Reynolds JC, Taylor AJ, Agodoa LY. Hospitalized atrial fibrillation after renal transplantation in the United States. Am J Transplant 2003; 3:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/35\">",
"      Siedlecki A, Foushee M, Curtis JJ, et al. The impact of left ventricular systolic dysfunction on survival after renal transplantation. Transplantation 2007; 84:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/36\">",
"      Gill JS, Ma I, Landsberg D, et al. Cardiovascular events and investigation in patients who are awaiting cadaveric kidney transplantation. J Am Soc Nephrol 2005; 16:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/37\">",
"      Fellstr&ouml;m B, Jardine AG, Soveri I, et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation 2005; 79:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/38\">",
"      Fellstr&ouml;m B, Jardine AG, Soveri I, et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transplant 2005; 5:1986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/39\">",
"      Bostom AG, Shemin D, Lapane KL, et al. Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: a matched case-control study. Atherosclerosis 1996; 125:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/40\">",
"      Guijarro C, Keane WF. Lipid abnormalities and changes in plasma proteins in glomerular diseases and chronic renal failure. Curr Opin Nephrol Hypertens 1993; 2:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/41\">",
"      Makita Z, Yanagisawa K, Kuwajima S, et al. The role of advanced glycosylation end-products in the pathogenesis of atherosclerosis. Nephrol Dial Transplant 1996; 11 Suppl 5:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/42\">",
"      Vanrenterghem Y, Ponticelli C, Morales JM, et al. Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant 2003; 3:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/43\">",
"      Shah N, Al-Khoury S, Afzali B, et al. Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors. Transplantation 2006; 81:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/44\">",
"      Lentine KL, Schnitzler MA, Abbott KC, et al. Incidence, predictors, and associated outcomes of atrial fibrillation after kidney transplantation. Clin J Am Soc Nephrol 2006; 1:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/45\">",
"      Molnar MZ, Czira M, Ambrus C, et al. Anemia is associated with mortality in kidney-transplanted patients--a prospective cohort study. Am J Transplant 2007; 7:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/46\">",
"      Kamar N, Rostaing L. Negative impact of one-year anemia on long-term patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycophenolate mofetil. Transplantation 2008; 85:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/47\">",
"      Gore JL, Pham PT, Danovitch GM, et al. Obesity and outcome following renal transplantation. Am J Transplant 2006; 6:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/48\">",
"      van den Ham EC, Kooman JP, Christiaans MH, van Hooff JP. Relation between steroid dose, body composition and physical activity in renal transplant patients. Transplantation 2000; 69:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/49\">",
"      de Vries AP, Bakker SJ, van Son WJ, et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant 2004; 4:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/50\">",
"      Courivaud C, Kazory A, Simula-Faivre D, et al. Metabolic syndrome and atherosclerotic events in renal transplant recipients. Transplantation 2007; 83:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/51\">",
"      Meier-Kriesche HU, Arndorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation 2002; 73:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/52\">",
"      van den Ham EC, Kooman JP, van Hooff JP. Nutritional considerations in renal transplant patients. Blood Purif 2002; 20:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/53\">",
"      Modanlou KA, Muthyala U, Xiao H, et al. Bariatric surgery among kidney transplant candidates and recipients: analysis of the United States renal data system and literature review. Transplantation 2009; 87:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/54\">",
"      Kasiske BL, Klinger D. Cigarette smoking in renal transplant recipients. J Am Soc Nephrol 2000; 11:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/55\">",
"      Cosio FG, Falkenhain ME, Pesavento TE, et al. Patient survival after renal transplantation: II. The impact of smoking. Clin Transplant 1999; 13:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/56\">",
"      Dennis VW, Robinson K. Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int Suppl 1996; 57:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/57\">",
"      Robinson K, Gupta A, Dennis V, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94:2743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/58\">",
"      Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/59\">",
"      Nyg&aring;rd O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/60\">",
"      Ducloux D, Motte G, Challier B, et al. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol 2000; 11:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/61\">",
"      Winkelmayer WC, Kramar R, Curhan GC, et al. Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: a prospective study. J Am Soc Nephrol 2005; 16:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/62\">",
"      Berger PB, Jones JD, Olson LJ, et al. Increase in total plasma homocysteine concentration after cardiac transplantation. Mayo Clin Proc 1995; 70:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/63\">",
"      Ambrosi P, Barlatier A, Habib G, et al. Hyperhomocysteinaemia in heart transplant recipients. Eur Heart J 1994; 15:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/64\">",
"      Arnadottir M, Hultberg B, Vladov V, et al. Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation 1996; 61:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/65\">",
"      Arnadottir M, Hultberg B, Wahlberg J, et al. Serum total homocysteine concentration before and after renal transplantation. Kidney Int 1998; 54:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/66\">",
"      Ducloux D, Fournier V, Rebibou JM, et al. Hyperhomocyst(e)inemia in renal transplant recipients with and without cyclosporine. Clin Nephrol 1998; 49:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/67\">",
"      Bostom AG, Gohh RY, Beaulieu AJ, et al. Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial. Ann Intern Med 1997; 127:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/68\">",
"      Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Circulation 2011; 123:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/69\">",
"      Zlotnick DM, Axelrod DA, Chobanian MC, et al. Non-invasive detection of pulmonary hypertension prior to renal transplantation is a predictor of increased risk for early graft dysfunction. Nephrol Dial Transplant 2010; 25:3090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/70\">",
"      Issa N, Krowka MJ, Griffin MD, et al. Pulmonary hypertension is associated with reduced patient survival after kidney transplantation. Transplantation 2008; 86:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/71\">",
"      Gaston RS, Kasiske BL, Fieberg AM, et al. Use of cardioprotective medications in kidney transplant recipients. Am J Transplant 2009; 9:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37977/abstract/72\">",
"      Pilmore HL, Skeans MA, Snyder JJ, et al. Cardiovascular disease medications after renal transplantation: results from the Patient Outcomes in Renal Transplantation study. Transplantation 2011; 91:542.",
"     </a>",
"    </li>",
"    <li>",
"     Lentine KL, Villines TC, Xiao H, et al. Cardioprotective medication use after acute myocardial infarction in kidney transplant recipients. Transplantation 2011.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7314 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-458F631DC3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_5_37977=[""].join("\n");
var outline_f37_5_37977=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW OF CARDIOVASCULAR RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H275228\">",
"      Myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H274573\">",
"      Prediction of cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H274580\">",
"      - Framingham risk score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H274587\">",
"      - Biomarkers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H274267\">",
"      Congestive heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44613340\">",
"      INDIVIDUAL RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3548021\">",
"      Pre-transplant cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44627677\">",
"      Dialysis vintage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4028198\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Obesity and metabolic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44627329\">",
"      Homocysteine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H240914\">",
"      Right heart failure and pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3548087\">",
"      RISK REDUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4028523\">",
"      Use of cardiovascular medications among kidney transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7314\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7314|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/8/39054\" title=\"figure 1\">",
"      Risk factors CV dis transplant",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/29/41433?source=related_link\">",
"      Anemia and the renal transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37685?source=related_link\">",
"      Cardiovascular risks of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28570?source=related_link\">",
"      Determinants and management of cardiovascular risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/55/26490?source=related_link\">",
"      Evaluation of the potential renal transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16761?source=related_link\">",
"      Hypertension after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29546?source=related_link\">",
"      Lipid abnormalities after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/40/26250?source=related_link\">",
"      New onset diabetes after transplant (NODAT) in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/35/3641?source=related_link\">",
"      Obesity, weight reduction, and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=related_link\">",
"      Overview of primary prevention of coronary heart disease and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17992?source=related_link\">",
"      Patient survival after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/34997?source=related_link\">",
"      Patterns of tobacco use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14170?source=related_link\">",
"      Risk factors for graft failure in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/20/12615?source=related_link\">",
"      Screening for and clinical evaluation of obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?15/2/15398?source=related_link\">",
"      Varenicline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17738?source=related_link\">",
"      Vascular calcification in chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_5_37978="Pulmonary complications of primary immunodeficiencies";
var content_f37_5_37978=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pulmonary complications of primary immunodeficiencies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/5/37978/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/5/37978/contributors\">",
"     Nicole M Chase, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/5/37978/contributors\">",
"     John M Routes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/5/37978/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/5/37978/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/5/37978/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/5/37978/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/5/37978/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/5/37978/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7222641\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary disease is common among patients with primary immunodeficiencies (PIDs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. As therapy for these disorders improves and life expectancy of patients with PIDs increases, the prevalence of pulmonary complications is likely to increase in parallel. Consequently, knowledge of the detection and management of pulmonary disorders related to PIDs is critical for optimal management.",
"   </p>",
"   <p>",
"    This topic will review the pulmonary findings that should raise suspicion of an underlying immune disorder, as well as the various pulmonary conditions that are seen in specific immunodeficiency disorders. Monitoring patients with PIDs for the development of pulmonary problems is also discussed. The evaluation of secondary immunodeficiency (eg, due to underlying diabetes, hemoglobinopathies, malignancy, HIV infection, drug-induced immunosuppression) and an overview of the medical management of patients with immunodeficiency are found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/26/43433?source=see_link&amp;anchor=H20#H20\">",
"     \"Approach to the adult with recurrent infections\", section on 'Respiratory tract infections'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/24/7561?source=see_link\">",
"     \"Secondary immune deficiency due to miscellaneous causes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29706?source=see_link\">",
"     \"Secondary immune deficiency induced by drugs and biologics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23102063\">",
"    <span class=\"h1\">",
"     PULMONARY MANIFESTATIONS OF IMMUNODEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spectrum of pulmonary manifestations in PIDs is broad and includes acute and chronic infection, structural abnormalities (eg, bronchiectasis), malignancy, and dysregulated inflammation resulting in tissue damage (eg, granuloma, pulmonary fibrosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. Pulmonary disease may be the initial manifestation of a PID, and certain clinical and radiographic findings, such as specific types of pulmonary infections and structural lung abnormalities, should prompt an immunologic evaluation for an underlying PID, regardless of patient age. The laboratory tests used to evaluate the immune system are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7222648\">",
"    <span class=\"h2\">",
"     Pulmonary infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections that are recurrent, recalcitrant to usual therapy, or due to opportunistic or unusual pathogens are suggestive of a possible underlying PID.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7222655\">",
"    <span class=\"h3\">",
"     Recurrent infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the general population, recurrent pneumonias (ie,",
"    <span class=\"nowrap\">",
"     &gt;two/lifetime)",
"    </span>",
"    are unusual. The association of pneumonia with recurrent sinus infections is also a clue that a PID may be present.",
"   </p>",
"   <p>",
"    Recurrent pneumonias in a specific lobe are suggestive of structural abnormalities, such as aberrant lung development, neoplasm, or the presence of a foreign body. Pneumonias confined to dependent lobes may indicate recurrent aspiration due to gastroesophageal reflux disease or swallowing abnormalities. In contrast, pneumonias in varying locations of the lung, particularly with interim clearing between episodes, are more indicative of underlying immune dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. The presence of unusual complications of pneumonia, such as pneumatoceles or cavitary lesions, is also concerning for immunodeficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/26/43433?source=see_link\">",
"     \"Approach to the adult with recurrent infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7222662\">",
"    <span class=\"h3\">",
"     Recalcitrant infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most uncomplicated community-acquired pneumonias respond to outpatient treatment with oral antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/15\">",
"     15",
"    </a>",
"    ]. The need for protracted courses of antibiotics for resolution of a pneumonia or the presence of complicated pneumonia (eg, multilobar opacities, empyema, lung abscess) requiring inpatient hospitalization or surgical intervention suggests a more severe infection phenotype. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31514?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23945?source=see_link&amp;anchor=H14#H14\">",
"     \"Nonresolving pneumonia\", section on 'Host factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/55/2938?source=see_link&amp;anchor=H23#H23\">",
"     \"Epidemiology, pathogenesis, and etiology of pneumonia in children\", section on 'Special populations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7222669\">",
"    <span class=\"h3\">",
"     Opportunistic/unusual pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with milder forms of PID (eg, less severe antibody defects) may not be susceptible to opportunistic or unusual pathogens. In such patients, the only clue to underlying PID is the increased frequency or severity of sinopulmonary infections caused by common organisms, such as Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17209?source=see_link\">",
"     \"Selective antibody deficiency with normal immunoglobulins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/60/13258?source=see_link\">",
"     \"IgG subclass deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/63/24570?source=see_link\">",
"     \"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, patients with more severe PIDs, especially those impairing T cell or phagocyte function, are at increased risk of infection with opportunistic or unusual pathogens. Pneumonia caused by Pneumocystis jirovecii, Pseudomonas, Burkholderia, Aspergillus, or CMV is rare among individuals with normal immune function who have not been recently hospitalized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. Identification of these",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other unusual organisms should heighten suspicion for an underlying PID, such as disorders of primary phagocytic function (eg, chronic granulomatous disease), or combined immunodeficiencies (eg, severe combined immunodeficiency, or SCID). The other clinical manifestations and evaluation of these infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21273?source=see_link\">",
"     \"Pulmonary infections in immunocompromised patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22665?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/51/36664?source=see_link\">",
"     \"Cytomegalovirus infection and disease in newborns, infants, children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nontuberculous mycobacterial infections also can occur in the context of immunodeficiencies, particularly when there is impaired",
"    <span class=\"nowrap\">",
"     IL-12/IL-23/interferon",
"    </span>",
"    gamma (IFN-&gamma;) signaling, or the presence of autoantibodies to IFN-&gamma;. Impaired signaling can be caused by defects in the IFN-&gamma; receptors, the IL-12 receptor &beta;1 component, the IL-12 p40 subunit, or the signal transducer and activator of transcription 1 (STAT1) factor. In addition, nontuberculous mycobacterial infection has been described in patients with defective regulation of NF-kappa-B (NF-kappa-B essential modifier or NEMO defects) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/20\">",
"     20",
"    </a>",
"    ]. The evaluation of these defects is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25288?source=see_link\">",
"     \"Pathogenesis of nontuberculous mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/12/4297?source=see_link\">",
"     \"Mendelian susceptibility to mycobacterial diseases (MSMD)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/58/40873?source=see_link&amp;anchor=H19#H19\">",
"     \"Combined immunodeficiencies\", section on 'NEMO and NFKBIA (IKBA) deficiencies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1322618\">",
"    <span class=\"h2\">",
"     Specific types of structural/functional lung abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain pulmonary findings are often noted in patients with primary immunodeficiency (PID), particularly in the context of recurrent infection or other signs of immunodeficiency, such as autoimmunity and malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1322625\">",
"    <span class=\"h3\">",
"     Hilar and/or mediastinal adenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracic lymph nodes greater than 1.0 cm in diameter are considered enlarged; nodes greater than 2.0 cm in diameter are virtually always abnormal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/15\">",
"     15",
"    </a>",
"    ]. Mediastinal adenopathy may be an incidental finding on chest radiography, although cough or chest pain may be present. Among patients with PID, there are myriad causes of thoracic adenopathy, and the presence or absence of generalized lymphadenopathy (ie, enlargement of &ge;three noncontiguous lymph nodes) can be a helpful differentiating feature, as described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/40/32392?source=see_link\">",
"     \"Anterior mediastinal mass lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/24/31111?source=see_link\">",
"     \"Evaluation of mediastinal masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Localized hilar",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mediastinal adenopathy can be seen in the context of infection (eg, tuberculosis, histoplasmosis), although it is classically associated with either malignancy or granulomatous inflammation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/15\">",
"       15",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Primary malignancy (eg, lymphoma) or secondary malignancy (eg, metastatic gastric carcinoma, as seen in common variable immunodeficiency): Numerous PIDs, such as common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, ataxia-telangiectasia (AT), and cartilage-hair hypoplasia, are associated with an increased risk of malignancy, and may present initially with thoracic adenopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/22,23\">",
"       22,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Granulomatous inflammation: Hilar",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mediastinal adenopathy occurring with granulomatous lung involvement, manifest as parenchymal nodules",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ground glass abnormalities, are commonly seen in CVID, and can be seen in chronic granulomatous disease (CGD). The presence of granuloma can be related to infection or chronic inflammation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Generalized adenopathy commonly results from systemic infection, rheumatologic disease, or secondary immunodeficiency (eg, AIDS). PIDs that are associated with diffuse adenopathy include autoimmune lymphoproliferative syndrome (ALPS), certain variants of hyper IgM syndrome, CVID and other disorders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1322632\">",
"    <span class=\"h3\">",
"     Obstructive lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain types of obstructive lung disease are seen in patients with PIDs, including bronchiectasis and bronchiolitis obliterans. Obstructive lung disease may be detected with the use of routine spirometry, which demonstrates a decreased ratio of the forced expiratory volume in one second (FEV1) to the forced vital capacity (FVC). A mixed obstructive-restrictive pattern may be seen in these patients and requires measurement of lung volumes for characterization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1322639\">",
"    <span class=\"h4\">",
"     Bronchiectasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of bronchiectasis, the presence of dilated and thickened airways, is a common pathologic response to repeated pyogenic infections",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    airways inflammation. PIDs are often implicated in the development of bronchiectasis, although other processes (eg, cystic fibrosis, ciliary dysfunction, recurrent aspiration, and scarring from prior infections) are in the differential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/9,25-27\">",
"     9,25-27",
"    </a>",
"    ]. Similar to recurrent pneumonia, bronchiectasis limited to dependent lung regions or a localized area of the lung should raise suspicion for a cause other than PID, such as recurrent aspiration pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bronchiectasis can develop as a consequence of any PID that predisposes to recurrent, pyogenic infection of the lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/28-31\">",
"     28-31",
"    </a>",
"    ], although patients with primary antibody deficiencies (eg, X-linked agammaglobulinemia, CVID) and disorders of phagocyte dysfunction (eg, chronic granulomatous disease [CGD]) are particularly susceptible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/43/16057?source=see_link\">",
"     \"Causes of bronchiectasis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early forms of bronchiectasis may be reversible, while more advanced forms (eg, saccular bronchiectasis) result in irreversible impairment. Chronic productive cough and dyspnea are common, particularly during infectious episodes, although many patients with bronchiectasis are asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/32\">",
"     32",
"    </a>",
"    ]. Obstructive impairment (ie, reduced or normal forced vital capacity (FVC), low forced expiratory volume (FEV1), and low",
"    <span class=\"nowrap\">",
"     FEV1/FVC)",
"    </span>",
"    is the most frequent finding, but a very low FVC can also be seen in advanced disease, when much of the lung has been destroyed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44662?source=see_link\">",
"     \"Clinical manifestations and evaluation of bronchiectasis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/10/12458?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bronchiectasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Routine chest radiographs are insensitive in detecting bronchiectasis, although increased peribronchial markings may occasionally be present. High resolution computed tomography (HRCT) of the chest is the gold standard for the diagnosis of bronchiectasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/25,33,34\">",
"     25,33,34",
"    </a>",
"    ]. Typical HRCT findings of bronchiectasis include parallel (tram) lines and dilated bronchi that are usually 1.5 times wider in diameter than the accompanying pulmonary artery branch. This cross-sectional configuration resembles a signet ring, thus the name &ldquo;signet ring sign&rdquo;. Airways affected by bronchiectasis may contain mucopurulent plugs or debris accompanied by postobstructive air trapping. When small airways are affected, peripheral, irregular, short (2 to 4 mm) linear branching markings are noted and are called \"tree-in-bud pattern\" opacities (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52831 \" href=\"mobipreview.htm?34/52/35649\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=see_link&amp;anchor=H21#H21\">",
"     \"High resolution computed tomography of the lungs\", section on 'Airway diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1322646\">",
"    <span class=\"h4\">",
"     Bronchiolitis obliterans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concentric luminal narrowing of the bronchioles due to inflammation and fibrosis is commonly referred to as bronchiolitis obliterans (BO), or obliterative bronchiolitis. BO may develop after inhalation of toxic fumes, pulmonary infection (eg, Mycoplasma, Legionella), in the context of rheumatologic disease, or after bone",
"    <span class=\"nowrap\">",
"     marrow/hematopoietic",
"    </span>",
"    stem cell or",
"    <span class=\"nowrap\">",
"     lung/heart-lung",
"    </span>",
"    transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/15\">",
"     15",
"    </a>",
"    ]. BO is associated with nonspecific clinical complaints, such as insidious cough and dyspnea.",
"   </p>",
"   <p>",
"    In constrictive bronchiolitis, tests of lung function may be normal or show obstructive changes with air trapping. Diffusing capacity (DLCO) is usually reduced, particularly as the disease progresses. Resting hypoxemia is frequently present. The combination of fixed, rather than reversible, obstructive airways disease on spirometry, plus a gas transfer defect manifest by a low DLCO or hypoxemia on exertion, is suggestive of BO. Other clues include the absence of radiographic evidence of bronchiectasis, or a severity of airflow obstruction that seems out of proportion to the degree of bronchiectasis. BO has been reported in patients with severe combined immunodeficiency (SCID), ataxia-telangiectasia, and CVID [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chest x-ray is insensitive for the diagnosis of BO, although bronchial wall thickening or hyperinflation may be noted. HRCT may be normal or can show nonspecific ground-glass opacities, centrilobular nodularity, air trapping, or bronchial wall thickening (eg, centrilobular nodules and \"v\" or \"y\" shaped branching linear opacities) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/15,38\">",
"     15,38",
"    </a>",
"    ]. Obtaining inspiratory and expiratory HRCT images may help identify air trapping (mosaic or diffuse), but the absence of air trapping does not exclude the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24247?source=see_link\">",
"     \"Bronchiolitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24247?source=see_link&amp;anchor=H12#H12\">",
"     \"Bronchiolitis in adults\", section on 'Chest imaging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/44/16074?source=see_link&amp;anchor=H58728348#H58728348\">",
"     \"Bronchiolitis in infants and children: Clinical features and diagnosis\", section on 'Chest radiograph'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If histologic confirmation of BO is required, surgical lung biopsy (open or thoracoscopic) is preferred over transbronchial biopsy, as it provides better sampling of the scattered areas of BO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24247?source=see_link&amp;anchor=H14#H14\">",
"     \"Bronchiolitis in adults\", section on 'Lung biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24247?source=see_link&amp;anchor=H6#H6\">",
"     \"Bronchiolitis in adults\", section on 'Constrictive bronchiolitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1322653\">",
"    <span class=\"h3\">",
"     Restrictive lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with certain PIDs can develop restrictive pulmonary physiology, including diffuse interstitial lung disease, organizing pneumonia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infiltrative disorders (eg, lymphoma, granuloma). Restrictive lung disease is suggested by a decreased forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) with concomitant normal or increased",
"    <span class=\"nowrap\">",
"     FEV1/FVC",
"    </span>",
"    by spirometry, although formal diagnosis requires direct measurement of lung volumes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/60/19402?source=see_link\">",
"     \"Cryptogenic organizing pneumonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4952?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of pulmonary function testing in adults\", section on 'Pulmonary function tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1322660\">",
"    <span class=\"h4\">",
"     Interstitial lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;ILD, or interstitial pneumonitis, encompasses a broad group of disease processes that result in inflammatory and fibrotic infiltration of the respiratory interstitium. ILD can be seen in patients with CVID or ataxia-telangiectasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Alternatively, ILD may be idiopathic (eg, sarcoidosis, idiopathic pulmonary fibrosis) or secondary to connective tissue diseases, drugs, or",
"    <span class=\"nowrap\">",
"     occupational/environmental",
"    </span>",
"    exposures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/34/14888?source=see_link\">",
"     \"Differential diagnosis and evaluation of multiple pulmonary nodules\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/22/26985?source=see_link\">",
"     \"Approach to the infant and child with interstitial lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1322667\">",
"    <span class=\"h4\">",
"     Organizing pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organizing pneumonia (OP), formerly known as bronchiolitis obliterans organizing pneumonia or BOOP, occurs as a consequence of a variety of disease processes (eg, infection, rheumatologic disease,",
"    <span class=\"nowrap\">",
"     marrow/stem",
"    </span>",
"    cell or",
"    <span class=\"nowrap\">",
"     lung/heart-lung",
"    </span>",
"    transplantation, inhalation of toxic fumes) and drug exposures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/15\">",
"     15",
"    </a>",
"    ]. Organizing pneumonia is called cryptogenic organizing pneumonia when it is idiopathic. A number of case reports have described OP developing in the course of CVID, although the mechanism is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/42-45\">",
"     42-45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/60/19402?source=see_link\">",
"     \"Cryptogenic organizing pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with OP often present with subacute cough and dyspnea, and clinical examination may reveal fine inspiratory crackles and tachypnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/39\">",
"     39",
"    </a>",
"    ]. A mild to moderate restrictive ventilatory defect is most common, although lung function is occasionally normal. The diffusing capacity (DLCO) is reduced in the majority of patients. Resting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exercise arterial hypoxemia (each defined by an alveolar-arterial oxygen gradient greater than 20 mmHg) are present in more than 80 percent of subjects. Radiographically, OP is associated with scattered, bilateral alveolar opacities and patchy areas of ground-glass attenuation or consolidation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/60/19402?source=see_link&amp;anchor=H3#H3\">",
"     \"Cryptogenic organizing pneumonia\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to OP, the differential diagnosis of unresolving radiographic opacities usually includes lung infection and malignancy. Flexible bronchoscopy with bronchoalveolar lavage is usually performed to obtain samples for microbiologic and cytologic analysis. If the diagnosis remains unclear, surgical lung biopsy (open or via thoracotomy) is often needed, as transbronchial biopsy may not obtain an adequate amount of tissue to differentiate OP from irreversible interstitial lung disease (ILD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/15\">",
"     15",
"    </a>",
"    ]. Pathologically, OP is characterized by scattered collections of proliferating fibroblasts within peribronchiolar air spaces and alveolar ducts, resulting in persistent alveolar inflammation and fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the most important features of OP is that it typically responds to oral glucocorticoid therapy, with complete radiographic clearing over weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/39,43-45\">",
"     39,43-45",
"    </a>",
"    ]. In the reported cases of OP associated with PID, the response to glucocorticoids was similar to that seen in cryptogenic OP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/42-45\">",
"     42-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1322674\">",
"    <span class=\"h4\">",
"     Granuloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The finding of granulomatous inflammation in the lung is nonspecific, and may be associated with infectious or noninfectious processes (",
"    <a class=\"graphic graphic_table graphicRef56028 \" href=\"mobipreview.htm?4/54/4972\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/15,46\">",
"     15,46",
"    </a>",
"    ]. Granulomas may be seen in mycobacterial, fungal, and parasitic infections. Noninfectious etiologies include sarcoidosis, hypersensitivity pneumonitis, vasculitides, drug reactions (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ), lymphoma, and pneumoconioses. Investigations into the etiology of granulomatous lung disease should proceed in a strategic manner, beginning with a thorough patient history of symptoms and time course, followed by studies to determine if pathogenic organisms can be identified, first by noninvasive means followed by an examination of tissue for histologic analysis and culture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9098?source=see_link\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/4/23625?source=see_link\">",
"     \"Tuberculosis disease in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21881?source=see_link\">",
"     \"Diagnosis and treatment of pulmonary histoplasmosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/27/13751?source=see_link\">",
"     \"Laboratory diagnosis of coccidioidomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain PIDs are particularly associated with the development of pulmonary granulomas. For example, patients with CGD are predisposed to infection with fungal pathogens and to granuloma formation in the absence of identifiable infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/48\">",
"     48",
"    </a>",
"    ]. Patients with CVID develop noncaseating granulomas for unknown reasons, although elevated levels of tumor necrosis factor (TNF) due to TNF polymorphisms have been implicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/28/17866?source=see_link\">",
"     \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7222676\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION OF PULMONARY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with suspected or known PID-related pulmonary disease, a systematic approach to diagnostic testing can help expedite and define the goals of treatment. Depending on the clinical history and",
"    <span class=\"nowrap\">",
"     acuity/severity",
"    </span>",
"    of the pulmonary process, multiple diagnostic modalities may be needed to establish a diagnosis. Radiographic and laboratory studies are generally employed initially, and histologic and functional testing can further define the disease process and identify therapeutic goals. For patients with known PIDs, knowledge of the primary immune defect, immunologic sequelae of any treatment(s) the patient has received, and the patient&rsquo;s recent environmental exposure history is essential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7222683\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the radiographic evaluation of pulmonary disease, a conventional chest radiograph is the initial radiographic modality for detecting acute pneumonia in children and adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. In all age groups, however, chest x-ray is insensitive for detection of certain structural abnormalities, such as bronchiectasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/28,51\">",
"     28,51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/62/5096?source=see_link\">",
"     \"Evaluation of diffuse lung disease by conventional chest radiography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Computed tomography (CT) of the chest with contrast is usually obtained when hilar",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mediastinal adenopathy are suspected based on the chest radiograph. A high resolution computed tomography (HRCT) scan of the chest is obtained in patients with known or suspected PID when the chest radiograph reveals lung parenchymal findings (eg, ground-glass opacities, nodular lesions, or other signs of interstitial lung disease, pneumatoceles or cavitary lesions) or does not clearly define the etiology of the patient&rsquo;s pulmonary symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/4,28,29,52,53\">",
"     4,28,29,52,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=see_link\">",
"     \"High resolution computed tomography of the lungs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional diagnostic studies, such as thoracic ultrasound and positron emission tomography, may be necessary for further evaluation of specific thoracic abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/60/23497?source=see_link\">",
"     \"Ataxia-telangiectasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20362?source=see_link\">",
"     \"T cell negative, B cell negative, NK cell positive severe combined immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7222690\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with pulmonary disease due to suspected or known PID, particularly those who are severely ill, the clinician should consider early use of specialized laboratory testing for definitive diagnosis of the underlying immunodeficiency (if not yet determined) and the infecting organism.",
"   </p>",
"   <p>",
"    The initial evaluation of immune function in patients with recurrent, recalcitrant, or opportunistic infections includes a complete blood count and differential, serum levels of IgG, IgA, IgM, and IgE, and a total hemolytic complement. Abnormal numbers of white blood cells should be further evaluated with flow cytometric evaluation of lymphocyte subsets (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23656?source=see_link\">",
"     \"Flow cytometry for the diagnosis of primary immunodeficiencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further evaluation is usually performed with guidance from an immunology specialist. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30458?source=see_link&amp;anchor=H23#H23\">",
"     \"Approach to the child with recurrent infections\", section on 'Laboratory evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/26/43433?source=see_link&amp;anchor=H24#H24\">",
"     \"Approach to the adult with recurrent infections\", section on 'Initial immunologic evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Microbiologic evaluation to identify the specific infecting organism in patients with pneumonia or a flare of bronchiectasis includes cultures from blood, sputum,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bronchoalveolar lavage, antigen detection assays, and antigen-specific polymerase chain reaction (PCR) tests. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17591?source=see_link\">",
"     \"Sputum cultures for the evaluation of bacterial pneumonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/51/25402?source=see_link&amp;anchor=H24#H24\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\", section on 'Microbiologic assays'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=see_link\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/3/38970?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serologic testing for antibodies to specific organisms (eg, atypical organisms, viral and fungal infections) may not be reliable in patients with PIDs that result in impaired antibody production (eg, combined immune deficiencies, primary antibody deficiencies). Serologies are also unreliable in patients receiving antibody replacement therapy, since the antibodies measured may have originated from the donors, rather than the patient. When the patient&rsquo;s ability to produce antibodies is in doubt, other diagnostic methods should be used (eg, direct culture, PCR, urine antigen testing). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=see_link\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/3/38970?source=see_link&amp;anchor=H25#H25\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Serology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H340053055\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients six years of age and older with evidence of pulmonary disease and known or suspected PID, spirometry plus direct measurement of lung volumes (eg, plethysmography) and assessment of diffusing capacity (DLCO), are typically performed soon after diagnosis, at a time when the patient is clinically stable. Subsequently, pulmonary function tests are obtained for monitoring and in response to changes in respiratory symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29112?source=see_link\">",
"     \"Overview of pulmonary function testing in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7400?source=see_link\">",
"     \"Diffusing capacity for carbon monoxide\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If obstructive impairment is noted on spirometry, the patient should be assessed for reversibility after bronchodilator administration. This is useful to screen for other disease processes that may be present, such as asthma, or to aid in determining the chronicity of other conditions, such as bronchiectasis. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/61/22487?source=see_link&amp;anchor=H6#H6\">",
"     \"Use of pulmonary function testing in the diagnosis of asthma\", section on 'Bronchodilator responses'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A six-minute walk is useful in the evaluation of patients with more advanced pulmonary disease, such as those with a low resting pulse oximetry, a forced vital capacity (FVC) less than 50 percent of predicted, complaint of dyspnea on exertion, or radiographic diffuse parenchymal lung disease. The six-minute walk test assesses exercise tolerance and also hypoxemia with activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/55-57\">",
"     55-57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7222697\">",
"    <span class=\"h2\">",
"     Histologic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic examination of pulmonary tissue or",
"    <span class=\"nowrap\">",
"     mediastinal/hilar",
"    </span>",
"    lymph nodes is important if the cause of lung infection, bronchiolitis, diffuse parenchymal lung disease, or",
"    <span class=\"nowrap\">",
"     mediastinal/hilar",
"    </span>",
"    adenopathy is unclear. The choice of procedure for obtaining tissue depends on the type and location of the abnormality and the anticipated sample size needed for diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lung tissue can be obtained by transbronchial biopsy during bronchoscopy, particularly when the goal is obtaining tissue for microbiologic staining and culture. Flexible bronchoscopy is minimally invasive and provides easy access to the lung via the airways [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Surgical lung biopsy is typically needed for conditions such as interstitial lung disease (ILD), bronchiolitis, or suspected malignancy, since transbronchial biopsy may not yield sufficient tissue for diagnostic purposes. Surgical lung biopsy may be obtained by video-assisted thorascopic surgery (VATS) or thoracotomy. VATS is increasingly considered to be the optimal modality, as it generally decreases the complications associated with open lung biopsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/32,59-61\">",
"       32,59-61",
"      </a>",
"      ]. VATS is well-tolerated in children, and is associated with less postoperative pain, better postoperative pulmonary function, and shorter hospital stays compared with open thoracotomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/62\">",
"       62",
"      </a>",
"      ]. However, more central lesions and larger peripheral lesions may not be amenable to VATS. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/424?source=see_link\">",
"       \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with mediastinal adenopathy, biopsies of enlarged nodes are obtained via endobronchial ultrasound-guided transbronchial needle aspiration, endoscopic ultrasound-guided needle aspiration, or mediastinoscopy. The choice among these procedures depends on local expertise and on the exact location of the adenopathy (",
"      <a class=\"graphic graphic_figure graphicRef63771 \" href=\"mobipreview.htm?0/10/167\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/32/19976?source=see_link&amp;anchor=H9#H9\">",
"       \"Endobronchial ultrasound: Indications, advantages, and complications\", section on 'Mediastinal lesions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/16/12552?source=see_link\">",
"       \"Endoscopic ultrasound-guided fine-needle aspiration in the mediastinum\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/27/32183?source=see_link\">",
"       \"Surgical management of mediastinal lymphadenopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23102184\">",
"    <span class=\"h1\">",
"     MONITORING FOR PULMONARY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a patient has been diagnosed with a PID, monitoring of lung function and prompt recognition of new complications are important components of medical management because pulmonary disease is a leading cause of morbidity and mortality in these patients. However, the optimal type and frequency of testing is not known; the suggestions listed here are based on clinical experience.",
"   </p>",
"   <p>",
"    Patients should be asked regularly about the onset of new pulmonary symptoms, including cough, dyspnea, sputum production, hemoptysis, or reduced exercise tolerance and also about any changes in sputum volume or color.",
"   </p>",
"   <p>",
"    Spirometry is a relatively inexpensive, low-risk means of obtaining reproducible measures of lung function. We typically perform repeat spirometry at regular intervals (eg, every 6 to 12 months) to monitor for the development",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progression of lung disease, even in those who are currently asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/25,63\">",
"     25,63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/30/5607?source=see_link\">",
"     \"Office spirometry\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29112?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of pulmonary function testing in children\", section on 'Spirometry'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We often repeat spirometry after treatment of an intercurrent flare of bronchiectasis to determine whether the course of antibiotics has returned the patient&rsquo;s lung function to baseline. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/11/38073?source=see_link\">",
"     \"Treatment of bronchiectasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lung volume measurements to assess for the development of a new restrictive process are generally not necessary as part of routine surveillance, but are indicated if a patient reports a change in exercise tolerance or if diffuse parenchymal lung disease is noted on imaging studies. We monitor patients with documented restrictive lung disease with routine lung volume measurements (eg, every 6 to 12 months).",
"   </p>",
"   <p>",
"    Patients with PIDs usually require periodic imaging to diagnose new pulmonary disorders and manage existing ones, especially when a change occurs in their clinical condition. We typically obtain a conventional chest radiograph if a patient reports an acute change in symptoms, in order to exclude pneumonia, lung abscess, or empyema. Thoracic computed tomography (CT) is obtained when a patient has a decrease in lung volumes or diffusing capacity on pulmonary function testing, when findings on the chest radiograph require further delineation, and if the patient experiences hemoptysis. High resolution CT (HRCT) is used in the initial diagnosis of bronchiectasis and in the evaluation of diffuse parenchymal lung disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=see_link\">",
"     \"High resolution computed tomography of the lungs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of radiation-based imaging studies in patients with PID must be conservative and thoughtful, since immunodeficient patients are at higher risk for malignancies at baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/64-67\">",
"     64-67",
"    </a>",
"    ]. Clinicians should attempt to minimize cumulative radiation exposure by choosing computed tomography protocols that use reduced radiation dose intensity whenever possible. As an example, conventional CT of the chest uses substantially less radiation than HRCT. Radiation exposure is particularly relevant to patients with PIDs that predispose to radiation sensitivity, including ataxia-telangiectasia and certain forms of severe combined immunodeficiency (SCID) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/32\">",
"     32",
"    </a>",
"    ]. In these patients, it is important to discuss alternative imaging modalities with the performing radiologist, in order to minimize radiation exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7222774\">",
"    <span class=\"h1\">",
"     PULMONARY DISEASE IN SPECIFIC TYPES OF PID",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary manifestations of PIDs include infection, structural disease, and malignancy, as previously discussed. Pulmonary disorders are particularly prominent in certain PIDs, several of which are reviewed in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7222781\">",
"    <span class=\"h2\">",
"     Antibody defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;PIDs that involve significant defects in antibody production or function predispose patients to recurrent pneumonias and the development of bronchiectasis. The causative organisms are typically common respiratory tract bacteria. Patients with common variable immunodeficiency (CVID) may also develop various forms of diffuse parenchymal lung disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7222797\">",
"    <span class=\"h3\">",
"     Common variable immunodeficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common variable immunodeficiency (CVID) is a heterogeneous disorder that results in a low IgG and low IgA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IgM, diminished antigen-specific antibody response, and variable B-cell numbers. In addition, some patients with CVID have also have CD4+ T-cell lymphopenia. Patients with CVID typically present with recurrent upper and lower respiratory tract infections, including sinusitis, bronchitis, and pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Common pathogens include encapsulated and atypical bacteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/69-72\">",
"     69-72",
"    </a>",
"    ]. Immunoglobulin replacement has decreased the incidence of pneumonia and increased life expectancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with CVID are at increased risk to develop interstitial lung disease (ILD) and malignancy, especially B-cell lymphomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/28/17866?source=see_link\">",
"     \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1325793\">",
"    <span class=\"h4\">",
"     Obstructive diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchiectasis is the most common obstructive lung disease in patients with CVID, occurring in greater than 20 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/69,76\">",
"     69,76",
"    </a>",
"    ]. Patients with CVID may also have a concomitant history of asthma, although it can be difficult to differentiate a flare of bronchiectasis from asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/77\">",
"     77",
"    </a>",
"    ]. Both bronchiectasis and asthma can cause dyspnea, wheezing, cough, sputum production, and airflow limitation on spirometry.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1325857\">",
"    <span class=\"h4\">",
"     Restrictive diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ten to 25 percent of patients with CVID develop various forms of diffuse parenchymal lung disease (ILD), such as organizing pneumonia (OP), mucosa-associated lymphoid tissue (MALT) lymphoma, or granulomatous and lymphocytic interstitial lung disease (GLILD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/77-80\">",
"     77-80",
"    </a>",
"    ]. Since ILD may be missed by routine chest radiographs, high resolution computed tomography (HRCT) of the chest is indicated in the initial evaluation of patients with CVID. If diffuse parenchymal disease is present on HRCT of the chest, thoracoscopic or open lung biopsy may be necessary to establish the underlying diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several cases of extranodal marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) type involving the lung, pleura, or mediastinal lymph nodes have been reported among patients with CVID [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. HRCT patterns include diffuse reticular, nodular, and consolidative opacities. The diagnosis requires biopsy of affected tissue. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19610?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\", section on 'Extranodal (MALT) MZL'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Granulomatous and lymphocytic interstitial lung disease (GLILD) is defined by the presence of granulomatous and lymphoproliferative (eg, lymphocytic interstitial pneumonitis (LIP), follicular bronchiolitis) histopathologic patterns in the lung in an individual patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]. HRCT scan of the chest typically demonstrates ground glass and nodular opacities with hilar",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mediastinal adenopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. Splenomegaly and diffuse adenopathy is frequently found. Granulomas may be found in other organs including bone marrow, spleen, GI tract, skin, and liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/28/17866?source=see_link&amp;anchor=H1193500#H1193500\">",
"     \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\", section on 'Granulomatous infiltration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The etiology of GLILD is unknown. In a small cohort study, the majority of patients with GLILD were found to have HHV8 infection of the lung, suggesting that HHV8 may underlie the pulmonary and lymphoproliferative complications in a subgroup of patients with GLILD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/89,92\">",
"     89,92",
"    </a>",
"    ]. Overproduction of TNF-alpha may also contribute to the propagation of granulomatous disease in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/93-96\">",
"     93-96",
"    </a>",
"    ]. Patients with CVID and GLILD appear to be at increased risk for autoimmune diseases and malignancy, particularly non-Hodgkin&rsquo;s lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/78,79,88,97,98\">",
"     78,79,88,97,98",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/28/17866?source=see_link&amp;anchor=H1193493#H1193493\">",
"     \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\", section on 'Autoimmune disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/45/38617?source=see_link&amp;anchor=H10572417#H10572417\">",
"     \"Common variable immunodeficiency in children\", section on 'Autoimmune disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GLILD is sometimes misdiagnosed as sarcoidosis initially, because both involve pulmonary granuloma, often accompanied by hilar",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mediastinal adenopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/80,99\">",
"     80,99",
"    </a>",
"    ]. Sarcoidosis, however, has several features that distinguish it from GLILD, such as normal or elevated serum immunoglobulin levels and frequent spontaneous remissions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/28/17866?source=see_link&amp;anchor=H1193500#H1193500\">",
"     \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\", section on 'Granulomatous infiltration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of GLILD is associated with significant morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/79\">",
"     79",
"    </a>",
"    ]. Untreated GLILD frequently leads to progressive pulmonary fibrosis and respiratory failure. However, the optimal treatment of this disorder is unknown. The parenchymal disease is often poorly responsive to empiric glucocorticoid treatment. Small numbers of patients with GLILD have been successfully treated with TNF antagonists,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , or a combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/100\">",
"     100",
"    </a>",
"    ]. We monitor the response to therapy with interval HRCT of the chest and pulmonary function testing, including spirometry, lung volumes, and diffusing capacity (DLCO).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17898709\">",
"    <span class=\"h3\">",
"     X-linked agammaglobulinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;X-linked agammaglobulinemia (XLA) is caused by a mutation in Bruton&rsquo;s tyrosine kinase, leading to a defect in B-cell development and ultimately resulting in a lack of mature B-cells and a profound decrease in immunoglobulin production. Patients with XLA are predisposed to recurrent respiratory tract infection by encapsulated extracellular bacteria (eg, S. pneumoniae and H. influenzae), Mycoplasma species, and less commonly Staphylococcus aureus and Pseudomonas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/70,71,101,102\">",
"     70,71,101,102",
"    </a>",
"    ]. Empiric treatment of sinopulmonary infections in patients with XLA should include coverage of atypical bacteria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21321?source=see_link\">",
"     \"Agammaglobulinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunoglobulin therapy has increased the life expectancy and decreased the number of pulmonary infections in patients with XLA. However, severe bronchiectasis and cor pulmonale remain a significant cause of morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/5,20,32,52,53,68,101,103\">",
"     5,20,32,52,53,68,101,103",
"    </a>",
"    ]. The early diagnosis and treatment of XLA is important in the prevention and progression of bronchiectasis, although bronchiectasis may develop despite high-dose gammaglobulin replacement therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. When present, bronchiectasis in XLA is generally restricted to the middle and lower lobes; upper lobe disease is uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/5,52,106\">",
"     5,52,106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High resolution computed tomography (HRCT) of the chest and pulmonary function tests should be performed in the initial evaluation of these patients to ascertain the presence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extent of bronchiectasis, and to assess the functional status of the lungs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/30,52\">",
"     30,52",
"    </a>",
"    ]. Unlike CVID, XLA does not appear to be associated with an increased incidence of interstitial lung disease or lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7222834\">",
"    <span class=\"h2\">",
"     Combined immunodeficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most characteristic pulmonary manifestations of combined immunodeficiencies are infections. Viral pathogens and opportunistic infections are common. Patients with these PIDs also develop interstitial lung disease (ILD) and lymphadenopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7222843\">",
"    <span class=\"h3\">",
"     Severe combined immunodeficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term severe combined immunodeficiency (SCID) refers to a group of life-threatening primary immunodeficiency disorders that present in infancy with T-cell lymphopenia and extreme susceptibility to infection with bacteria, viruses, and fungi (",
"    <a class=\"graphic graphic_table graphicRef77724 \" href=\"mobipreview.htm?17/53/18268\">",
"     table 2",
"    </a>",
"    ). Pulmonary manifestations of SCID generally include opportunistic infections and interstitial lung disease, commonly due to Pneumocystis jirovecii, cytomegalovirus, adenovirus, respiratory syncytial virus,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parainfluenza virus type 3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/107\">",
"     107",
"    </a>",
"    ]. Identification of patients with SCID at an early age is critical to prevent the development of pulmonary infections. Patients receiving hematopoietic stem cell transplantation before the age of four months have significantly better survival outcomes, especially if transplant occurs prior to the development of opportunistic infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/108\">",
"     108",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/10?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): Specific defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with adenosine deaminase (ADA) deficiency (ADA-SCID) may have specific pulmonary findings that are distinct from other forms of SCID. ADA-SCID patients frequently have characteristic chest x-ray findings, including flaring of the anterior ribs, shortening of the transverse vertebral processes with flattening of the ends (platyspondyly) and thick growth arrest lines. They also have an increased susceptibility to pulmonary insufficiency, possibly due to accumulation of adenosine in the lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. Prior descriptions of this phenomenon have been nonspecific, suggesting symptoms of idiopathic respiratory distress or reactive airway disease. However, one case report described a patient with progressive tachypnea and cough, leading to hypoxemia and the need for supplemental oxygen therapy. Diffuse, progressive interstitial lung disease was detected radiographically. Histologic analysis revealed diffuse interstitial goblet cell hyperplasia, and dense inflammatory infiltrates composed of plasma cells, eosinophils, and lymphocytes. Immunohistochemistry was positive for CD8+ T-cells, CD20+ B-cells, and CD68+ macrophages. The patient&rsquo;s lung disease dramatically improved after treatment with pegylated-ADA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/111\">",
"     111",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/27/2488?source=see_link\">",
"     \"Adenosine deaminase deficiency: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7222850\">",
"    <span class=\"h3\">",
"     Ataxia-telangiectasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ataxia-telangiectasia (AT) is an autosomal recessive disorder in which DNA repair is impaired by defects in the ataxia-telangiectasia mutated (ATM) gene, rendering patients exquisitely sensitive to ionizing radiation. Clinically, AT is characterized by cellular and humoral immune deficits, progressive neurologic dysfunction with ataxia, and increased risk of malignancy. The presentation of AT is diverse and varies among patients. Despite the fact that AT is technically a combined immunodeficiency, severe bacterial, viral, and opportunistic infections are uncommon in AT. Patients generally develop recurrent sinopulmonary infections due to common pathogens (eg, Pseudomonas, Haemophilus, and pneumococcus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. Neurologic defects leading to poor swallowing can also predispose to recurrent aspiration pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/60/23497?source=see_link\">",
"     \"Ataxia-telangiectasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with AT suffer from various forms of pulmonary disease, which confer significant morbidity and mortality. The most common disorders are recurrent infections and bronchiectasis, but also bronchiolitis obliterans and interstitial lung disease (ILD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/36,113-115\">",
"     36,113-115",
"    </a>",
"    ]. In patients with AT, symptoms of ILD are usually nonspecific, including cough, dyspnea and fever. Early identification of AT-related ILD and assessment of therapeutic response is often limited by reluctance to perform radiographic studies out of concern for radiation sensitivity; for this reason, patients with AT should receive care at specialized centers with expertise in managing this disorder.",
"   </p>",
"   <p>",
"    In a series of 97 patients with AT and lung disease, 25 had interstitial lung disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/114\">",
"     114",
"    </a>",
"    ]. The mean age of onset of ILD was 17.5 years with a range of 9 to 28 years. Computed tomography of the chest in five patients revealed diffuse bibasilar reticular and nodular opacities and interlobular septal thickening, but no honeycomb changes. Pleural thickening or effusion was noted in some patients. Histologically, patients with AT-related ILD demonstrate fibrosis with diffuse lymphocytic, lymphohistiocytic, or rarely neutrophilic, parenchymal infiltration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/114\">",
"     114",
"    </a>",
"    ]. Clonal analyses must be performed to exclude the possibility of malignancy, a known complication of AT. Atypical epithelial and interstitial cells with large hyperchromatic and pleomorphic nuclei are frequently seen, but are of unclear significance.",
"   </p>",
"   <p>",
"    AT-related ILD is often progressive despite antibiotics, oxygen therapy, or supplemental immunoglobulin. In the series mentioned previously, oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy was helpful only in patients with early stage ILD; it was not sufficient to prevent mortality in patients with severe disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/114\">",
"     114",
"    </a>",
"    ]. The initial dose was 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for the first month with a subsequent taper over two to three months.",
"   </p>",
"   <p>",
"    AT also predisposes affected individuals to a &gt;100-fold increased risk of malignancy, most commonly",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/116\">",
"     116",
"    </a>",
"    ]. In a review of AT patients diagnosed with Hodgkin&rsquo;s lymphoma, fever, cough and adenopathy were associated with the presence of lymphoma, and mortality was 100 percent",
"    <span class=\"nowrap\">",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/117\">",
"      117",
"     </a>",
"     ].",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7222857\">",
"    <span class=\"h3\">",
"     CD40/CD40 ligand deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;CD40/CD40",
"    ligand deficiency, which accounts for most cases of hyper IgM syndrome (HIGM), causes T cell dysfunction and hypogammaglobulinemia, with variably elevated levels of IgM. Patients with CD40 or CD40 ligand (CD40L) deficiency usually present within the first two years of life with the combination of recurrent upper and lower respiratory tract infections (primarily caused by encapsulated bacteria) and opportunistic infections. Other defects have been associated with elevated levels of IgM and immunodeficiency, as discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/58/40873?source=see_link\">",
"     \"Combined immunodeficiencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/32/21001?source=see_link\">",
"     \"Hyperimmunoglobulin M syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with HIGM are susceptible to pulmonary infection from a wide range of pathogens, including bacteria, viruses, and fungi. Opportunistic pathogens, such as P. jirovecii and CMV, are common and frequently result in mortality in untreated individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. Disseminated Histoplasma infection involving the lung has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/120\">",
"     120",
"    </a>",
"    ]. Other fungal infections, such as Cryptococcus sp., may involve the hilar",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mediastinal lymph nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/121,122\">",
"     121,122",
"    </a>",
"    ]. Autoimmunity and malignancy are also increased in patients with HIGM, but generally spare the thorax [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7222864\">",
"    <span class=\"h2\">",
"     Other immunodeficiencies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1323800\">",
"    <span class=\"h3\">",
"     Chronic granulomatous disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic granulomatous disease (CGD) is an inherited disorder of phagocyte function, characterized by a mutation in one of five genes that encode NADPH oxidase, a key enzyme responsible for the intracellular generation of reactive oxygen intermediates. CGD manifests clinically as recurrent bacterial and fungal infections due to catalase positive organisms. Pulmonary infection, including pneumonia, lung abscess,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    empyema formation, is the leading manifestation of CGD. Aspergillus is the most common pathogen; other associated organisms include S. aureus, Nocardia (which frequently results in pulmonary cavitation), and Burkholderia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/48,124\">",
"     48,124",
"    </a>",
"    ]. Patients are also susceptible to infection with both M. tuberculosis and nontuberculous mycobacteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/48,125\">",
"     48,125",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/36/10826?source=see_link\">",
"     \"Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/12/11465?source=see_link\">",
"     \"Chronic granulomatous disease: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pneumonia can be complicated by empyema or pulmonary abscess in as many as 20 percent of patients with CGD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/126\">",
"     126",
"    </a>",
"    ]. Contiguous spread to the pleura, bone, and ultimately disseminated infection is particularly common with pulmonary infections caused by Aspergillus nidulans. Pulmonary infections tend to be protracted, and mediastinal and hilar adenopathy is common.",
"   </p>",
"   <p>",
"    Noninfectious pulmonary granulomas occur, although less frequently than pneumonia or abscess formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/48\">",
"     48",
"    </a>",
"    ]. Reasons for the development of noninfectious granuloma in CGD are unclear, but dysregulated inflammation is commonly implicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/127-130\">",
"     127-130",
"    </a>",
"    ]. In some patients, granuloma formation is seen with concurrent lymphocytic infiltrate; some authors have termed this &ldquo;autoimmune granuloma&rdquo;, based on resolution of these findings after initiation of immunomodulatory therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/131\">",
"     131",
"    </a>",
"    ]. Granuloma formation in the chest may be mistaken for malignancy or sarcoidosis on imaging studies; review of the infectious history or development of infection after treatment (eg, glucocorticoids for sarcoidosis) ultimately leads to the diagnosis of CGD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/48,132-135\">",
"     48,132-135",
"    </a>",
"    ]. However, concomitant CGD and sarcoidosis (glucocorticoid-responsive noncaseating granulomata) of the lungs and central nervous system have also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/134,136\">",
"     134,136",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulmonary imaging findings in patients with CGD are often nonspecific; chest CT scans may reveal consolidation, ground-glass or tree-in-bud opacities, scattered nodules,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bronchiectasis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55108 \" href=\"mobipreview.htm?6/49/6934\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/135,137,138\">",
"     135,137,138",
"    </a>",
"    ]. Hilar",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mediastinal adenopathy are also seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/137\">",
"     137",
"    </a>",
"    ]. Furthermore, imaging may reveal extrapulmonary thoracic disease, including contiguous spread of infection to the ribs or vertebrae, resulting clinically in osteomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/137\">",
"     137",
"    </a>",
"    ]. Focal scarring and honeycomb formation may follow lung infection.",
"   </p>",
"   <p>",
"    Given the broad spectrum of pathogens implicated in CGD, effort should be made to identify a causative organism prior to initiating treatment. In particular, special emphasis should be placed on obtaining a thorough exposure history in patients who present acutely with fever, dyspnea and diffuse pulmonary infiltrates, as acute, fulminant, mulch-related pneumonitis has been observed and constitutes a medical emergency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/139,140\">",
"     139,140",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/12/11465?source=see_link\">",
"     \"Chronic granulomatous disease: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognosis of patients with CGD has improved with antifungal and antibacterial prophylaxis and the administration of interferon-gamma with approximately 55 percent survival at age 30. Patients with CGD do not appear to have an increased predisposition to develop malignancy. Mortality in CGD is generally due to pneumonia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sepsis, with Aspergillus most frequently implicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/48,124\">",
"     48,124",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/12/11465?source=see_link&amp;anchor=H14#H14\">",
"     \"Chronic granulomatous disease: Treatment and prognosis\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7222873\">",
"    <span class=\"h3\">",
"     Hyper IgE syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyper IgE syndrome (HIES) is a group of diseases that present with elevated IgE, recurrent pneumonia, and eczema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/141\">",
"     141",
"    </a>",
"    ]. Autosomal dominant hyper IgE syndrome is due to mutations in STAT3, and is additionally associated with pneumatocele formation, skeletal disease (eg, fractures, scoliosis), and vascular abnormalities (eg, cerebral aneurysms, thrombotic events) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/142-144\">",
"     142-144",
"    </a>",
"    ]. There are also autosomal recessive forms of HIES caused by mutations in other molecules; these are associated with other clinical findings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/25/32153?source=see_link\">",
"     \"Hyperimmunoglobulin E syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pneumonia is common in patients with all forms of hyper IgE syndrome, and is generally due to infection with S. aureus, S. pneumoniae, or H. influenzae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/145,146\">",
"     145,146",
"    </a>",
"    ]. Patients with STAT3 mutations are known to develop bronchiectasis and are uniquely susceptible to secondary pneumatocele formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/146\">",
"     146",
"    </a>",
"    ]. Pneumatocele superinfection, particularly with Pseudomonas and Aspergillus, is a leading cause of mortality in patients with autosomal dominant HIES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/147\">",
"     147",
"    </a>",
"    ]. Nontuberculous mycobacteria have also been found in HIES patients with pneumatoceles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/148\">",
"     148",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with hyper IgE syndrome are predisposed to malignancy; one case series reported the increase in relative risk of lymphoma at &gt;250, although this was not stratified according to molecular defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/5/37978/abstract/149\">",
"     149",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7222880\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary disease is a common manifestation of many primary immunodeficiencies (PIDs) and a leading cause of morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H7222641\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infections that are recurrent, recalcitrant to therapy, or due to opportunistic or unusual pathogens suggest a possible underlying PID. (See",
"      <a class=\"local\" href=\"#H7222648\">",
"       'Pulmonary infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other pulmonary manifestations of PIDs include bronchiectasis, bronchiolitis obliterans, disordered inflammatory responses (such as granuloma), interstitial lung disease, mediastinal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hilar adenopathy, and malignancy. (See",
"      <a class=\"local\" href=\"#H23102063\">",
"       'Pulmonary manifestations of immunodeficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the initial evaluation of patients with PIDs that are frequently complicated by pulmonary abnormalities, high resolution computed tomography of the chest can reveal pulmonary abnormalities that are not detected by standard chest radiographs or pulmonary function tests, including plethysmography and diffusing capacity (DLCO). (See",
"      <a class=\"local\" href=\"#H7222676\">",
"       'Diagnostic evaluation of pulmonary disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with PID and interstitial lung disease or suspected malignancy, surgical biopsy using video-assisted thorascopic surgery (VATS) or thoracotomy may be necessary to obtain sufficient pulmonary tissue to definitively establish a diagnosis. (See",
"      <a class=\"local\" href=\"#H7222697\">",
"       'Histologic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine monitoring for the development of pulmonary disease is essential in all patients with PIDs. (See",
"      <a class=\"local\" href=\"#H23102184\">",
"       'Monitoring for pulmonary disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/1\">",
"      Marcy TW, Reynolds HY. Pulmonary consequences of congenital and acquired primary immunodeficiency states. Clin Chest Med 1989; 10:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/2\">",
"      Bode FR, Par&eacute; JA, Fraser RG. Pulmonary diseases in the compromised host. A review of clinical and roentgenographic manifestations in patients with impaired host defense mechanisms. Medicine (Baltimore) 1974; 53:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/3\">",
"      Williams DM, Krick JA, Remington JS. Pulmonary infection in the compromised host: part I. Am Rev Respir Dis 1976; 114:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/4\">",
"      Pennington DJ, Lonergan GJ, Benya EC. Pulmonary disease in the immunocompromised child. J Thorac Imaging 1999; 14:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/5\">",
"      Buckley RH. Pulmonary complications of primary immunodeficiencies. Paediatr Respir Rev 2004; 5 Suppl A:S225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/6\">",
"      Moskaluk CA, Pogrebniak HW, Pass HI, et al. Surgical pathology of the lung in chronic granulomatous disease. Am J Clin Pathol 1994; 102:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/7\">",
"      Dukes RJ, Rosenow EC 3rd, Hermans PE. Pulmonary manifestations of hypogammaglobulinaemia. Thorax 1978; 33:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/8\">",
"      Kohler P. Pulmonary manifestations and management of antibody deficiency in adults. Chest 1984; 86:24S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/9\">",
"      Bilton D. Update on non-cystic fibrosis bronchiectasis. Curr Opin Pulm Med 2008; 14:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/10\">",
"      Reynolds JH, McDonald G, Alton H, Gordon SB. Pneumonia in the immunocompetent patient. Br J Radiol 2010; 83:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/11\">",
"      S&aacute;nchez I, Navarro H, M&eacute;ndez M, et al. Clinical characteristics of children with tracheobronchial anomalies. Pediatr Pulmonol 2003; 35:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/12\">",
"      Vaughan D, Katkin JP. Chronic and recurrent pneumonias in children. Semin Respir Infect 2002; 17:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/13\">",
"      McGarry T, Giosa R, Rohman M, Huang CT. Pneumatocele formation in adult pneumonia. Chest 1987; 92:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/14\">",
"      Antachopoulos C, Walsh TJ, Roilides E. Fungal infections in primary immunodeficiencies. Eur J Pediatr 2007; 166:1099.",
"     </a>",
"    </li>",
"    <li>",
"     Mason RJ, Broaddus VC, Martin TR, et al. Murray and Nadel's textbook of respiratory medicine, 5th ed, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/16\">",
"      Apisarnthanarak A, Mundy LM. Etiology of community-acquired pneumonia. Clin Chest Med 2005; 26:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/17\">",
"      de la Hoz RE, Stephens G, Sherlock C. Diagnosis and treatment approaches of CMV infections in adult patients. J Clin Virol 2002; 25 Suppl 2:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/18\">",
"      Williams BJ, Dehnbostel J, Blackwell TS. Pseudomonas aeruginosa: host defence in lung diseases. Respirology 2010; 15:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/19\">",
"      Bodey GP, Vartivarian S. Aspergillosis. Eur J Clin Microbiol Infect Dis 1989; 8:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/20\">",
"      Bousfiha A, Picard C, Boisson-Dupuis S, et al. Primary immunodeficiencies of protective immunity to primary infections. Clin Immunol 2010; 135:204.",
"     </a>",
"    </li>",
"    <li>",
"     Longo DL. Harrison's hematology and oncology, McGraw-Hill, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/22\">",
"      Salavoura K, Kolialexi A, Tsangaris G, Mavrou A. Development of cancer in patients with primary immunodeficiencies. Anticancer Res 2008; 28:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/23\">",
"      Shapiro RS. Malignancies in the setting of primary immunodeficiency: Implications for hematologists/oncologists. Am J Hematol 2011; 86:48.",
"     </a>",
"    </li>",
"    <li>",
"     Ochs HD, Smith CIE, Puck JM. Primary immunodeficiency diseases: A molecular and cellular approach, 2nd ed, Oxford University Press, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/25\">",
"      Stafler P, Carr SB. Non-cystic fibrosis bronchiectasis: its diagnosis and management. Arch Dis Child Educ Pract Ed 2010; 95:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/26\">",
"      Li AM, Sonnappa S, Lex C, et al. Non-CF bronchiectasis: does knowing the aetiology lead to changes in management? Eur Respir J 2005; 26:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/27\">",
"      Boren EJ, Teuber SS, Gershwin ME. A review of non-cystic fibrosis pediatric bronchiectasis. Clin Rev Allergy Immunol 2008; 34:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/28\">",
"      Obregon RG, Lynch DA, Kaske T, et al. Radiologic findings of adult primary immunodeficiency disorders. Contribution of CT. Chest 1994; 106:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/29\">",
"      Zonana J, Elder ME, Schneider LC, et al. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am J Hum Genet 2000; 67:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/30\">",
"      Aghamohammadi A, Allahverdi A, Abolhassani H, et al. Comparison of pulmonary diseases in common variable immunodeficiency and X-linked agammaglobulinaemia. Respirology 2010; 15:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/31\">",
"      Niehues T, Reichenbach J, Neubert J, et al. Nuclear factor kappaB essential modulator-deficient child with immunodeficiency yet without anhidrotic ectodermal dysplasia. J Allergy Clin Immunol 2004; 114:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/32\">",
"      Tarzi MD, Grigoriadou S, Carr SB, et al. Clinical immunology review series: An approach to the management of pulmonary disease in primary antibody deficiency. Clin Exp Immunol 2009; 155:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/33\">",
"      Jeanes AC, Owens CM. Chest imaging in the immunocompromised child. Paediatr Respir Rev 2002; 3:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/34\">",
"      Goeminne P, Dupont L. Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century. Postgrad Med J 2010; 86:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/35\">",
"      Deerojanawong J, Chang AB, Eng PA, et al. Pulmonary diseases in children with severe combined immune deficiency and DiGeorge syndrome. Pediatr Pulmonol 1997; 24:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/36\">",
"      Ito M, Nakagawa A, Hirabayashi N, Asai J. Bronchiolitis obliterans in ataxia-telangiectasia. Virchows Arch 1997; 430:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/37\">",
"      Thickett KM, Kumararatne DS, Banerjee AK, et al. Common variable immune deficiency: respiratory manifestations, pulmonary function and high-resolution CT scan findings. QJM 2002; 95:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/38\">",
"      Pipavath SJ, Lynch DA, Cool C, et al. Radiologic and pathologic features of bronchiolitis. AJR Am J Roentgenol 2005; 185:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/39\">",
"      Ryu JH, Myers JL, Swensen SJ. Bronchiolar disorders. Am J Respir Crit Care Med 2003; 168:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/40\">",
"      Cha SI, Fessler MB, Cool CD, et al. Lymphoid interstitial pneumonia: clinical features, associations and prognosis. Eur Respir J 2006; 28:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/41\">",
"      Nicholson AG. Lymphocytic interstitial pneumonia and other lymphoproliferative disorders in the lung. Semin Respir Crit Care Med 2001; 22:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/42\">",
"      Kaufman J, Komorowski R. Bronchiolitis obliterans organizing pneumonia in common variable immunodeficiency syndrome. Chest 1991; 100:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/43\">",
"      Tanaka N, Kim JS, Bates CA, et al. Lung diseases in patients with common variable immunodeficiency: chest radiographic, and computed tomographic findings. J Comput Assist Tomogr 2006; 30:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/44\">",
"      Wislez M, Sibony M, Naccache JM, et al. Organizing pneumonia related to common variable immunodeficiency. case report and literature review. Respiration 2000; 67:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/45\">",
"      Gamboa PM, Merino JM, Maruri N, Mart&iacute;n-Granizo IF. Hypogammaglobulinemia resembling BOOP. Allergy 2000; 55:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/46\">",
"      Mukhopadhyay S. Role of histology in the diagnosis of infectious causes of granulomatous lung disease. Curr Opin Pulm Med 2011; 17:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/47\">",
"      Mukhopadhyay S, Gal AA. Granulomatous lung disease: an approach to the differential diagnosis. Arch Pathol Lab Med 2010; 134:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/48\">",
"      van den Berg JM, van Koppen E, Ahlin A, et al. Chronic granulomatous disease: the European experience. PLoS One 2009; 4:e5234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/49\">",
"      Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.",
"     </a>",
"    </li>",
"    <li>",
"     Cincinnati Children&rsquo;s Hospital and Medical Center. Evidence-based care guideline for community acquired pneumonia in children 60 days through 17 years of age. file://www.guidelines.gov/content.aspx?id=9690. (Accessed on February 05, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/51\">",
"      Ognibene FP, Pass HI, Roth JA, et al. Role of imaging and interventional techniques in the diagnosis of respiratory disease in the immunocompromised host. J Thorac Imaging 1988; 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/52\">",
"      Newson T, Chippindale AJ, Cant AJ. Computed tomography scan assessment of lung disease in primary immunodeficiencies. Eur J Pediatr 1999; 158:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/53\">",
"      Rusconi F, Panisi C, Dellepiane RM, et al. Pulmonary and sinus diseases in primary humoral immunodeficiencies with chronic productive cough. Arch Dis Child 2003; 88:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/54\">",
"      Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/55\">",
"      Rasekaba T, Lee AL, Naughton MT, et al. The six-minute walk test: a useful metric for the cardiopulmonary patient. Intern Med J 2009; 39:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/56\">",
"      Enright PL. The six-minute walk test. Respir Care 2003; 48:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/57\">",
"      Chetta A, Aiello M, Foresi A, et al. Relationship between outcome measures of six-minute walk test and baseline lung function in patients with interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/58\">",
"      Deterding RR, Wagener JS. Lung biopsy in immunocompromised children: when, how, and who? J Pediatr 2000; 137:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/59\">",
"      Sigurdsson MI, Isaksson HJ, Gudmundsson G, Gudbjartsson T. Diagnostic surgical lung biopsies for suspected interstitial lung diseases: a retrospective study. Ann Thorac Surg 2009; 88:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/60\">",
"      Lee YC, Wu CT, Hsu HH, et al. Surgical lung biopsy for diffuse pulmonary disease: experience of 196 patients. J Thorac Cardiovasc Surg 2005; 129:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/61\">",
"      Riley DJ, Costanzo EJ. Surgical biopsy: its appropriateness in diagnosing interstitial lung disease. Curr Opin Pulm Med 2006; 12:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/62\">",
"      Engum SA. Minimal access thoracic surgery in the pediatric population. Semin Pediatr Surg 2007; 16:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/63\">",
"      Rich AL, Le Jeune IR, McDermott L, Kinnear WJ. Serial lung function tests in primary immune deficiency. Clin Exp Immunol 2008; 151:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/64\">",
"      Cunningham-Rundles C. Lung disease, antibodies and other unresolved issues in immune globulin therapy for antibody deficiency. Clin Exp Immunol 2009; 157 Suppl 1:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/65\">",
"      Touw CM, van de Ven AA, de Jong PA, et al. Detection of pulmonary complications in common variable immunodeficiency. Pediatr Allergy Immunol 2010; 21:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/66\">",
"      Turner PJ, Mehr S, Kemp AS. Detection of pulmonary complications in common variable immunodeficiency. Pediatr Allergy Immunol 2011; 22:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/67\">",
"      van de Ven AA, de Jong PA, Terheggen-Lagro SW, van Montfrans JM. High-resolution computed tomography in pediatric common variable immunodeficiency: risks and benefits. Pediatr Allergy Immunol 2011; 22:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/68\">",
"      Sweinberg SK, Wodell RA, Grodofsky MP, et al. Retrospective analysis of the incidence of pulmonary disease in hypogammaglobulinemia. J Allergy Clin Immunol 1991; 88:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/69\">",
"      Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999; 92:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/70\">",
"      Roifman CM, Rao CP, Lederman HM, et al. Increased susceptibility to Mycoplasma infection in patients with hypogammaglobulinemia. Am J Med 1986; 80:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/71\">",
"      Gelfand EW. Unique susceptibility of patients with antibody deficiency to mycoplasma infection. Clin Infect Dis 1993; 17 Suppl 1:S250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/72\">",
"      Oksenhendler E, G&eacute;rard L, Fieschi C, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis 2008; 46:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/73\">",
"      Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 2002; 109:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/74\">",
"      Rubin SA. Radiology of immunologic diseases of the lung. J Thorac Imaging 1988; 3:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/75\">",
"      Gregersen S, Aal&oslash;kken TM, Mynarek G, et al. Development of pulmonary abnormalities in patients with common variable immunodeficiency: associations with clinical and immunologic factors. Ann Allergy Asthma Immunol 2010; 104:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/76\">",
"      Mart&iacute;nez Garc&iacute;a MA, de Rojas MD, Nauffal Manzur MD, et al. Respiratory disorders in common variable immunodeficiency. Respir Med 2001; 95:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/77\">",
"      Busse PJ, Farzan S, Cunningham-Rundles C. Pulmonary complications of common variable immunodeficiency. Ann Allergy Asthma Immunol 2007; 98:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/78\">",
"      Wehr C, Kivioja T, Schmitt C, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood 2008; 111:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/79\">",
"      Bates CA, Ellison MC, Lynch DA, et al. Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency. J Allergy Clin Immunol 2004; 114:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/80\">",
"      Bouvry D, Mouthon L, Brillet PY, et al. Granulomatosis-associated common variable immunodeficiency disorder: a case-control study versus sarcoidosis. Eur Respir J 2013; 41:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/81\">",
"      Aghamohammadi A, Parvaneh N, Tirgari F, et al. Lymphoma of mucosa-associated lymphoid tissue in common variable immunodeficiency. Leuk Lymphoma 2006; 47:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/82\">",
"      Reichenberger F, Wyser C, Gonon M, et al. Pulmonary mucosa-associated lymphoid tissue lymphoma in a patient with common variable immunodeficiency syndrome. Respiration 2001; 68:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/83\">",
"      Cunningham-Rundles C, Cooper DL, Duffy TP, Strauchen J. Lymphomas of mucosal-associated lymphoid tissue in common variable immunodeficiency. Am J Hematol 2002; 69:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/84\">",
"      Arnold DF, Wiggins J, Cunningham-Rundles C, et al. Granulomatous disease: distinguishing primary antibody disease from sarcoidosis. Clin Immunol 2008; 128:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/85\">",
"      Mechanic LJ, Dikman S, Cunningham-Rundles C. Granulomatous disease in common variable immunodeficiency. Ann Intern Med 1997; 127:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/86\">",
"      Popa V. Lymphocytic interstitial pneumonia of common variable immunodeficiency. Ann Allergy 1988; 60:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/87\">",
"      Park JH, Levinson AI. Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). Clin Immunol 2010; 134:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/88\">",
"      Bondioni MP, Soresina A, Lougaris V, et al. Common variable immunodeficiency: computed tomography evaluation of bronchopulmonary changes including nodular lesions in 40 patients. Correlation with clinical and immunological data. J Comput Assist Tomogr 2010; 34:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/89\">",
"      Morimoto Y, Routes JM. Granulomatous disease in common variable immunodeficiency. Curr Allergy Asthma Rep 2005; 5:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/90\">",
"      Aghamohammadi A, Abolhassani H, Rezaei N, et al. Cutaneous granulomas in common variable immunodeficiency: case report and review of literature. Acta Dermatovenerol Croat 2010; 18:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/91\">",
"      Agarwal S, Smereka P, Harpaz N, et al. Characterization of immunologic defects in patients with common variable immunodeficiency (CVID) with intestinal disease. Inflamm Bowel Dis 2011; 17:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/92\">",
"      Wheat WH, Cool CD, Morimoto Y, et al. Possible role of human herpesvirus 8 in the lymphoproliferative disorders in common variable immunodeficiency. J Exp Med 2005; 202:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/93\">",
"      Pandolfi F, Paganelli R, Oliva A, et al. Increased IL-6 gene expression and production in patients with common variable immunodeficiency. Clin Exp Immunol 1993; 92:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/94\">",
"      Aukrust P, Lien E, Kristoffersen AK, et al. Persistent activation of the tumor necrosis factor system in a subgroup of patients with common variable immunodeficiency--possible immunologic and clinical consequences. Blood 1996; 87:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/95\">",
"      Mullighan CG, Fanning GC, Chapel HM, Welsh KI. TNF and lymphotoxin-alpha polymorphisms associated with common variable immunodeficiency: role in the pathogenesis of granulomatous disease. J Immunol 1997; 159:6236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/96\">",
"      Mullighan CG, Marshall SE, Bunce M, Welsh KI. Variation in immunoregulatory genes determines the clinical phenotype of common variable immunodeficiency. Genes Immun 1999; 1:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/97\">",
"      Mellemkjaer L, Hammarstrom L, Andersen V, et al. Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin Exp Immunol 2002; 130:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/98\">",
"      Cunningham-Rundles C, Lieberman P, Hellman G, Chaganti RS. Non-Hodgkin lymphoma in common variable immunodeficiency. Am J Hematol 1991; 37:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/99\">",
"      Fasano MB, Sullivan KE, Sarpong SB, et al. Sarcoidosis and common variable immunodeficiency. Report of 8 cases and review of the literature. Medicine (Baltimore) 1996; 75:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/100\">",
"      Chase NM, Verbsky JW, Hintermeyer MK, et al. Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID). J Clin Immunol 2013; 33:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/101\">",
"      Winkelstein JA, Marino MC, Lederman HM, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore) 2006; 85:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/102\">",
"      Conley ME, Rohrer J, Minegishi Y. X-linked agammaglobulinemia. Clin Rev Allergy Immunol 2000; 19:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/103\">",
"      Bondioni MP, Duse M, Plebani A, et al. Pulmonary and sinusal changes in 45 patients with primary immunodeficiencies: computed tomography evaluation. J Comput Assist Tomogr 2007; 31:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/104\">",
"      Plebani A, Soresina A, Rondelli R, et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol 2002; 104:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/105\">",
"      Kainulainen L, Varpula M, Liippo K, et al. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol 1999; 104:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/106\">",
"      Curtin JJ, Webster AD, Farrant J, Katz D. Bronchiectasis in hypogammaglobulinaemia--a computed tomography assessment. Clin Radiol 1991; 44:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/107\">",
"      Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol 2010; 125:S182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/108\">",
"      Myers LA, Patel DD, Puck JM, Buckley RH. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood 2002; 99:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/109\">",
"      Blackburn MR, Kellems RE. Adenosine deaminase deficiency: metabolic basis of immune deficiency and pulmonary inflammation. Adv Immunol 2005; 86:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/110\">",
"      Sauer AV, Aiuti A. New insights into the pathogenesis of adenosine deaminase-severe combined immunodeficiency and progress in gene therapy. Curr Opin Allergy Clin Immunol 2009; 9:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/111\">",
"      Somech R, Lai YH, Grunebaum E, et al. Polyethylene glycol-modified adenosine deaminase improved lung disease but not liver disease in partial adenosine deaminase deficiency. J Allergy Clin Immunol 2009; 124:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/112\">",
"      Nowak-Wegrzyn A, Crawford TO, Winkelstein JA, et al. Immunodeficiency and infections in ataxia-telangiectasia. J Pediatr 2004; 144:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/113\">",
"      Bott L, Lebreton J, Thumerelle C, et al. Lung disease in ataxia-telangiectasia. Acta Paediatr 2007; 96:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/114\">",
"      Schroeder SA, Swift M, Sandoval C, Langston C. Interstitial lung disease in patients with ataxia-telangiectasia. Pediatr Pulmonol 2005; 39:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/115\">",
"      McGrath-Morrow SA, Gower WA, Rothblum-Oviatt C, et al. Evaluation and management of pulmonary disease in ataxia-telangiectasia. Pediatr Pulmonol 2010; 45:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/116\">",
"      Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst 1986; 77:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/117\">",
"      Sandoval C, Swift M. Hodgkin disease in ataxia-telangiectasia patients with poor outcomes. Med Pediatr Oncol 2003; 40:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/118\">",
"      Winkelstein JA, Marino MC, Ochs H, et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore) 2003; 82:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/119\">",
"      Lougaris V, Badolato R, Ferrari S, Plebani A. Hyper immunoglobulin M syndrome due to CD40 deficiency: clinical, molecular, and immunological features. Immunol Rev 2005; 203:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/120\">",
"      Hostoffer RW, Berger M, Clark HT, Schreiber JR. Disseminated Histoplasma capsulatum in a patient with hyper IgM immunodeficiency. Pediatrics 1994; 94:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/121\">",
"      Lee MY, Chung JH, Shin JH, et al. Lymphonodular cryptococcosis diagnosed by fine needle aspiration cytology in hyper-IgM syndrome. A case report. Acta Cytol 2001; 45:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/122\">",
"      Antachopoulos C. Invasive fungal infections in congenital immunodeficiencies. Clin Microbiol Infect 2010; 16:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/123\">",
"      Jesus AA, Duarte AJ, Oliveira JB. Autoimmunity in hyper-IgM syndrome. J Clin Immunol 2008; 28 Suppl 1:S62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/124\">",
"      Winkelstein JA, Marino MC, Johnston RB Jr, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000; 79:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/125\">",
"      Lee PP, Chan KW, Jiang L, et al. Susceptibility to mycobacterial infections in children with X-linked chronic granulomatous disease: a review of 17 patients living in a region endemic for tuberculosis. Pediatr Infect Dis J 2008; 27:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/126\">",
"      Khanna G, Kao SC, Kirby P, Sato Y. Imaging of chronic granulomatous disease in children. Radiographics 2005; 25:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/127\">",
"      Morgenstern DE, Gifford MA, Li LL, et al. Absence of respiratory burst in X-linked chronic granulomatous disease mice leads to abnormalities in both host defense and inflammatory response to Aspergillus fumigatus. J Exp Med 1997; 185:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/128\">",
"      Meissner F, Seger RA, Moshous D, et al. Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease. Blood 2010; 116:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/129\">",
"      Sch&auml;ppi MG, Jaquet V, Belli DC, Krause KH. Hyperinflammation in chronic granulomatous disease and anti-inflammatory role of the phagocyte NADPH oxidase. Semin Immunopathol 2008; 30:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/130\">",
"      Rosenzweig SD. Inflammatory manifestations in chronic granulomatous disease (CGD). J Clin Immunol 2008; 28 Suppl 1:S67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/131\">",
"      De Ravin SS, Naumann N, Cowen EW, et al. Chronic granulomatous disease as a risk factor for autoimmune disease. J Allergy Clin Immunol 2008; 122:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/132\">",
"      Hauck F, Heine S, Beier R, et al. Chronic granulomatous disease (CGD) mimicking neoplasms: a suspected mediastinal teratoma unmasking as thymic granulomas due to X-linked CGD, and 2 related cases. J Pediatr Hematol Oncol 2008; 30:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/133\">",
"      McLean-Tooke AP, Aldridge C, Gilmour K, et al. An unusual cause of granulomatous disease. BMC Clin Pathol 2007; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/134\">",
"      Brunner J, Dockter G, R&ouml;sen-Wolff A, Roesler J. X-linked chronic granulomatous disease (CGD) caused by an intra-exonic splice mutation (CYBB exon 3, c.262G-&gt;A) is mimicking juvenile sarcoidosis. Clin Exp Rheumatol 2007; 25:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/135\">",
"      Godoy MC, Vos PM, Cooperberg PL, et al. Chest radiographic and CT manifestations of chronic granulomatous disease in adults. AJR Am J Roentgenol 2008; 191:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/136\">",
"      De Ravin SS, Naumann N, Robinson MR, et al. Sarcoidosis in chronic granulomatous disease. Pediatrics 2006; 117:e590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/137\">",
"      Towbin AJ, Chaves I. Chronic granulomatous disease. Pediatr Radiol 2010; 40:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/138\">",
"      Tabarsi P, Mirsaeidi M, Karimi S, et al. Lymphocytic bronchiolitis as presenting disorder in an undiagnosed adult patient with chronic granulomatous disease. Iran J Allergy Asthma Immunol 2007; 6:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/139\">",
"      Siddiqui S, Anderson VL, Hilligoss DM, et al. Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clin Infect Dis 2007; 45:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/140\">",
"      Ameratunga R, Woon ST, Vyas J, Roberts S. Fulminant mulch pneumonitis in undiagnosed chronic granulomatous disease: a medical emergency. Clin Pediatr (Phila) 2010; 49:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/141\">",
"      Freeman AF, Holland SM. Clinical manifestations of hyper IgE syndromes. Dis Markers 2010; 29:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/142\">",
"      Grimbacher B, Holland SM, Gallin JI, et al. Hyper-IgE syndrome with recurrent infections--an autosomal dominant multisystem disorder. N Engl J Med 1999; 340:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/143\">",
"      Holland SM, DeLeo FR, Elloumi HZ, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007; 357:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/144\">",
"      Minegishi Y, Saito M, Tsuchiya S, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007; 448:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/145\">",
"      Buckley RH, Wray BB, Belmaker EZ. Extreme hyperimmunoglobulinemia E and undue susceptibility to infection. Pediatrics 1972; 49:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/146\">",
"      Freeman AF, Holland SM. The hyper-IgE syndromes. Immunol Allergy Clin North Am 2008; 28:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/147\">",
"      Freeman AF, Kleiner DE, Nadiminti H, et al. Causes of death in hyper-IgE syndrome. J Allergy Clin Immunol 2007; 119:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/148\">",
"      Melia E, Freeman AF, Shea YR, et al. Pulmonary nontuberculous mycobacterial infections in hyper-IgE syndrome. J Allergy Clin Immunol 2009; 124:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/5/37978/abstract/149\">",
"      Leonard GD, Posadas E, Herrmann PC, et al. Non-Hodgkin's lymphoma in Job's syndrome: a case report and literature review. Leuk Lymphoma 2004; 45:2521.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15830 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-C1C910ED83-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_5_37978=[""].join("\n");
var outline_f37_5_37978=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7222880\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7222641\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23102063\">",
"      PULMONARY MANIFESTATIONS OF IMMUNODEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7222648\">",
"      Pulmonary infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7222655\">",
"      - Recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7222662\">",
"      - Recalcitrant infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7222669\">",
"      - Opportunistic/unusual pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1322618\">",
"      Specific types of structural/functional lung abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1322625\">",
"      - Hilar and/or mediastinal adenopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1322632\">",
"      - Obstructive lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1322639\">",
"      Bronchiectasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1322646\">",
"      Bronchiolitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1322653\">",
"      - Restrictive lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1322660\">",
"      Interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1322667\">",
"      Organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1322674\">",
"      Granuloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7222676\">",
"      DIAGNOSTIC EVALUATION OF PULMONARY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7222683\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7222690\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H340053055\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7222697\">",
"      Histologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23102184\">",
"      MONITORING FOR PULMONARY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7222774\">",
"      PULMONARY DISEASE IN SPECIFIC TYPES OF PID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7222781\">",
"      Antibody defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7222797\">",
"      - Common variable immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1325793\">",
"      Obstructive diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1325857\">",
"      Restrictive diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17898709\">",
"      - X-linked agammaglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7222834\">",
"      Combined immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7222843\">",
"      - Severe combined immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7222850\">",
"      - Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7222857\">",
"      - CD40/CD40 ligand deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7222864\">",
"      Other immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1323800\">",
"      - Chronic granulomatous disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7222873\">",
"      - Hyper IgE syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7222880\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/15830\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/15830|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?34/52/35649\" title=\"diagnostic image 1\">",
"      Tree-in-bud CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?6/49/6934\" title=\"diagnostic image 2\">",
"      Granulomatous lung involvement in CGD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/15830|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/10/167\" title=\"figure 1\">",
"      Mediastinal LN approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/15830|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/54/4972\" title=\"table 1\">",
"      Granulomatous lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/53/18268\" title=\"table 2\">",
"      SCID classification and gene defects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/27/2488?source=related_link\">",
"      Adenosine deaminase deficiency: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21321?source=related_link\">",
"      Agammaglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/40/32392?source=related_link\">",
"      Anterior mediastinal mass lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/26/43433?source=related_link\">",
"      Approach to the adult with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/51/25402?source=related_link\">",
"      Approach to the immunocompromised patient with fever and pulmonary infiltrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/22/26985?source=related_link\">",
"      Approach to the infant and child with interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/60/23497?source=related_link\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24247?source=related_link\">",
"      Bronchiolitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/44/16074?source=related_link\">",
"      Bronchiolitis in infants and children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/43/16057?source=related_link\">",
"      Causes of bronchiectasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/36/10826?source=related_link\">",
"      Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/12/11465?source=related_link\">",
"      Chronic granulomatous disease: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/3/38970?source=related_link\">",
"      Clinical features and diagnosis of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/10/12458?source=related_link\">",
"      Clinical manifestations and diagnosis of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44662?source=related_link\">",
"      Clinical manifestations and evaluation of bronchiectasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/28/17866?source=related_link\">",
"      Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19610?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/58/40873?source=related_link\">",
"      Combined immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/45/38617?source=related_link\">",
"      Common variable immunodeficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/60/19402?source=related_link\">",
"      Cryptogenic organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/51/36664?source=related_link\">",
"      Cytomegalovirus infection and disease in newborns, infants, children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21881?source=related_link\">",
"      Diagnosis and treatment of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9098?source=related_link\">",
"      Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/34/14888?source=related_link\">",
"      Differential diagnosis and evaluation of multiple pulmonary nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7400?source=related_link\">",
"      Diffusing capacity for carbon monoxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/32/19976?source=related_link\">",
"      Endobronchial ultrasound: Indications, advantages, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/16/12552?source=related_link\">",
"      Endoscopic ultrasound-guided fine-needle aspiration in the mediastinum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/55/2938?source=related_link\">",
"      Epidemiology, pathogenesis, and etiology of pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31514?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/62/5096?source=related_link\">",
"      Evaluation of diffuse lung disease by conventional chest radiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/24/31111?source=related_link\">",
"      Evaluation of mediastinal masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23656?source=related_link\">",
"      Flow cytometry for the diagnosis of primary immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/25/32153?source=related_link\">",
"      Hyperimmunoglobulin E syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/32/21001?source=related_link\">",
"      Hyperimmunoglobulin M syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/60/13258?source=related_link\">",
"      IgG subclass deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/27/13751?source=related_link\">",
"      Laboratory diagnosis of coccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/12/4297?source=related_link\">",
"      Mendelian susceptibility to mycobacterial diseases (MSMD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23945?source=related_link\">",
"      Nonresolving pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/30/5607?source=related_link\">",
"      Office spirometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29112?source=related_link\">",
"      Overview of pulmonary function testing in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25288?source=related_link\">",
"      Pathogenesis of nontuberculous mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21273?source=related_link\">",
"      Pulmonary infections in immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/24/7561?source=related_link\">",
"      Secondary immune deficiency due to miscellaneous causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29706?source=related_link\">",
"      Secondary immune deficiency induced by drugs and biologics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/63/24570?source=related_link\">",
"      Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17209?source=related_link\">",
"      Selective antibody deficiency with normal immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42471?source=related_link\">",
"      Severe combined immunodeficiency (SCID): An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/10?source=related_link\">",
"      Severe combined immunodeficiency (SCID): Specific defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17591?source=related_link\">",
"      Sputum cultures for the evaluation of bacterial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/27/32183?source=related_link\">",
"      Surgical management of mediastinal lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20362?source=related_link\">",
"      T cell negative, B cell negative, NK cell positive severe combined immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/11/38073?source=related_link\">",
"      Treatment of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/4/23625?source=related_link\">",
"      Tuberculosis disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/61/22487?source=related_link\">",
"      Use of pulmonary function testing in the diagnosis of asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_5_37979="Ranson criteria pancreatitis";
var content_f37_5_37979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ranson criteria to predict severity of acute pancreatitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"        0 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age",
"       </td>",
"       <td>",
"        &gt;55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        White blood cell count",
"       </td>",
"       <td>",
"        &gt;16,000/mm3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood glucose",
"       </td>",
"       <td>",
"        &gt;200 mg/dL (11.1 mmol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactate dehydrogenase",
"       </td>",
"       <td>",
"        &gt;350 U/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspartate aminotransferase (AST)",
"       </td>",
"       <td>",
"        &gt;250 U/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"        48 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematocrit",
"       </td>",
"       <td>",
"        Fall by &ge;10 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood urea nitrogen",
"       </td>",
"       <td>",
"        Increase by &ge;5 mg/dL (1.8 mmol/L) despite fluids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum calcium",
"       </td>",
"       <td>",
"        &lt;8 mg/dL (2 mmol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        pO2",
"       </td>",
"       <td>",
"        &lt;60 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Base deficit",
"       </td>",
"       <td>",
"        &gt;4 MEq/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluid sequestation",
"       </td>",
"       <td>",
"        &gt;6000 mL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The presence of 1 to 3 criteria represents mild pancreatitis; the mortality rate rises significantly with four or more criteria.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Ranson, JHC, Rifkind, KM, Roses, DF, et al, Surg Gynecol Obstet 1974; 139:69.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_5_37979=[""].join("\n");
var outline_f37_5_37979=null;
var title_f37_5_37980="Ingredient label terms for milk";
var content_f37_5_37980=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F63271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F63271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    How to read an ingredient label for a milk-free diet",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Avoid foods that contain milk or any of these ingredients:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Butter, butter fat, butter oil, butter acid, butter ester(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Buttermilk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Casein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Casein hydrolysate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caseinates (in all forms)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cheese",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cottage cheese",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Curds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Custard",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diacetyl",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ghee",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Half-and-half",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactalbumin, lactalbumin phosphate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactoferrin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactulose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Milk (in all forms, including condensed, derivative, dry, evaporated, goat's milk and milk from other animals, low fat, malted, milkfat, nonfat, powder, protein, skimmed, solids, whole)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Milk protein hydrolysate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pudding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recaldent&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rennet casein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sour cream, sour cream solids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sour milk solids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tagatose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Whey (in all forms)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Whey protein hydrolysate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yogurt",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Milk is sometimes found in the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Artificial butter flavor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Baked goods",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caramel candies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chocolate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactic acid starter culture and other bacterial cultures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Luncheon meat, hot dogs, sausages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Margarine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nisin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nondairy products",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nougat",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    All FDA-regulated manufactured food products that contain milk as an ingredient are required by US law to list the word \"milk\" on the product label.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; 2010 The Food Allergy &amp; Anaphylaxis Network. Used with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_5_37980=[""].join("\n");
var outline_f37_5_37980=null;
var title_f37_5_37981="Intracellular CPPD crystal";
var content_f37_5_37981=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55730&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55730&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intracellular calcium pyrophosphate dihydrate crystal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 285px; height: 189px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A faintly yellow, positively birefringent, rhomboidal, intracellular crystal characteristic of calcium pyrophosphate dihydrate (CPPD) is seen in the synovial fluid of a patient with pseudogout, when viewed with compensated, polarized microscopy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image courtesy of Ralph Schumacher, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_5_37981=[""].join("\n");
var outline_f37_5_37981=null;
var title_f37_5_37982="Middle phalanx fracture with impaction";
var content_f37_5_37982=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Middle phalanx fracture with impaction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 247px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anteroposterior x-ray reveals significant impaction of the ulnar plateau at the articular base of the middle phalanx.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Strickland JW, Graham TJ. Master Techniques in Orthopeadic Surgery: The Hand, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_5_37982=[""].join("\n");
var outline_f37_5_37982=null;
var title_f37_5_37983="Grovers disease";
var content_f37_5_37983=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Grover's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical appearance of scattered pruritic, erythematous papules and papulovesicles on the trunk.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Whitney High, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_5_37983=[""].join("\n");
var outline_f37_5_37983=null;
